Title: Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child anemia and micronutrient status: an individual participant data meta-analysis of randomized controlled trials

Author names: K. Ryan Wessells, Charles D. Arnold, Christine P. Stewart, Elizabeth L. Prado, Souheila Abbeddou, Seth Adu-Afarwuah, Benjamin F. Arnold, Per Ashorn, Ulla Ashorn, Elodie Becquey, Kenneth H. Brown, Kendra A. Byrd, Rebecca K. Campbell, Parul Christian, Lia C.H. Fernald, Yue-Mei Fan, Emanuela Galasso, Sonja Y. Hess, Lieven Huybregts, Josh M. Jorgensen, Marion Kiprotich, Emma Kortekangas, Anna Lartey, Agnes Le Port, Jef L. Leroy, Audrie Lin, Kenneth Maleta, Susana L. Matias, Mduduzi NN Mbuya, Malay K. Mridha, Kuda Mutasa, Abu Mohd. Naser, Rina R. Paul, Harriet Okronipa, Jean-Bosco Ouédraogo, Amy J. Pickering, Mahbubur Rahman, Kerry Schulze, Laura E. Smith, Ann M. Weber, Amanda Zongrone, Kathryn G. Dewey

Author affiliations:

Institute for Global Nutrition and Department of Nutrition, University of California, Davis, Davis, CA, USA (KRW, CDA, CPS, ELP, KHB, SYH, KGD)

Public Health Nutrition, Department of Public Health and Primary Care, University of Ghent, Ghent, 9000 Belgium (SA)

Department of Nutrition and Food Science, University of Ghana, Legon, Accra, Ghana (SAA, ALartey)

Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, CA, USA (BFA)

Center for Child Health Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland (PA, UA, YMF, EK)

Department of Paediatrics, Tampere University Hospital, Tampere, Finland (PA)

Poverty, Health, and Nutrition Division, International Food Policy Research Institute, 1201 I Street NW, Washington, DC, 20005, USA (EB, LH, JL)

WorldFish, Bayan Lepas, Penang, Malaysia (KAB)

Division of Epidemiology and Biostatistics, University of Illinois at Chicago School of Public Health, Chicago, IL, USA (RKC)

Program in Human Nutrition, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA (PC, KS)

School of Public Health, University of California, Berkeley, Berkeley, CA, USA (LCHF, ALin)

Development Research Group, World Bank, Washington DC, USA (EG)

Nutrition Program, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR, USA (JMJ)

One Acre Fund, Nairobi, Kenya (MK)

Independent consultant, Dakar, Senegal (ALP)

Department of Public Health, School of Public Health and Family Medicine, College of Medicine, University of Malawi, Blantyre, Malawi (KMaleta)

Department of Nutritional Sciences and Toxicology, University of California, Berkeley, Berkeley, CA, USA (SLM)

Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe (KMutasa, MNNM)

Global Alliance for Improved Nutrition, Washington, DC, USA (MNNM)

Center for Non-communicable Diseases and Nutrition, BRAC James P Grant School of Public Health, Bangladesh (MKM, RRP)

International Center for Diarrheal Diseases Research, Bangladesh (icddr,b) (AMN, MR)

Gangarosa Department of Environmental Health, Rollins School of Public Heath, Emory University, Atlanta, GA, USA (AMN)

Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY, USA (HO)

Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso, Burkina Faso (JBO)

School of Engineering, Tufts University, Medford, MA, USA (AJPickering)

School of Public Health and Health Professions, Department of Epidemiology and Environmental Health, The State University of New York at Buffalo, NY, USA (LES)

School of Community Health Sciences, Division of Epidemiology, University of Nevada, Reno, USA (AMW)

Independent Consultant, Washington, DC, USA (AZ)

Corresponding Author: K. Ryan Wessells, Department of Nutrition, University of California,

One Shields Ave., Davis, CA 95616; 530 400 3097; krwessells@ucdavis.edu

Sources of Support: Bill & Melinda Gates Foundation OPP49817

Short running head: Child SQ-LNS and micronutrient status

Abbreviations: AGP, α-1-acid glycoprotein; BMI, body-mass index; CRP, C-reactive protein;

GMR, geometric means ratio; Hb, hemoglobin; IPD, individual participant data; LNS, lipid-

based nutrient supplement; MD, mean difference; MN, micronutrient; MNP, multiple

micronutrient powder; MQ-LNS, medium-quantity lipid-based nutrient supplements; MUAC,

mid-upper arm circumference; PD, prevalence difference; pF, plasma ferritin; PR, prevalence

ratio; pZn, plasma zinc; RBP, retinol binding protein; RCT, randomized controlled trial; SES,

socio-economic status; SQ-LNS, small-quantity lipid-based nutrient supplements; sTfR, soluble

transferrin receptor; WASH, water sanitation and hygiene; WAZ, weight-for-age z-score; WLZ,

weight-for-length z-score; ZPP, zinc protoporphyrin

Registry and registry number for systematic reviews or meta-analyses: Registered at

www.crd.york.ac.uk/PROSPERO as CRD42020156663.

Data described in the manuscript, code book, and analytic code will not be made available

because they are compiled from 13 different trials, and access is under the control of the

investigators of each of those trials.

Parul Christian is a member of the Journal's Editorial Board.

18

19

20

21

22

23

potential study-level effect modifiers.

Background: Small-quantity lipid-based nutrient supplements (SQ-LNS) have been shown to 2 3 reduce the prevalence of anemia and iron deficiency among infants and young children, but 4 effects on other micronutrients are less well known. Identifying subgroups who may experience greater benefits from SQ-LNS, or who are more likely to respond to the intervention, may 5 6 facilitate the development of public health policies and programs. 7 **Objective:** Our objective was to identify study-level and individual-level modifiers of the effect 8 9 of SQ-LNS on child hematological and micronutrient status outcomes. 10 **Methods:** We conducted a two-stage meta-analysis of individual participant data from 13 11 12 randomized controlled trials of SO-LNS provided to children 6 to 24 months of age in low- and middle-income countries (n = 15,946). Outcomes were hemoglobin (Hb), inflammation-adjusted 13 plasma ferritin, soluble transferrin receptor, zinc, retinol and retinol binding protein (RBP), and 14 erythrocyte zinc protoporphyrin, and respective dichotomous outcomes indicative of anemia and 15 micronutrient deficiency. We generated study-specific estimates of SO-LNS vs. control, 16 including main effects and subgroup estimates for individual-level effect modifiers, and pooled 17

Results: Provision of SQ-LNS decreased the prevalence of anemia (Hb < 110 g/L) by 16% (relative reduction), iron deficiency (plasma ferritin < 12 μ g/L) by 56% and iron deficiency anemia (IDA; Hb < 110 g/L and plasma ferritin < 12 μ g/L) by 64%. We observed positive

the estimates using fixed-effects models. We used random effects meta-regression to examine

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

5

effects of SO-LNS on hematological and iron status outcomes within all subgroups of the studylevel and individual-level effect modifiers, but effects were larger in certain subgroups. For example, effects of SQ-LNS on anemia and iron status were greater in trials that provided SQ-LNS for > 12 months and provided 9 mg/d vs. < 9 mg iron/d, and among later-born (vs. firstborn) children. There was no effect of SQ-LNS on plasma zinc or retinol, but there was a 7% increase in plasma RBP and a 56% reduction in vitamin A deficiency (RBP < 0.70 µmol/L), with little evidence of effect modification by individual-level characteristics. Conclusions: SQ-LNS provided to infants and young children 6-24 months of age can substantially reduce the prevalence of anemia, iron deficiency, and IDA across a range of individual, population and study design characteristics. Policy-makers and program planners should consider SO-LNS within intervention packages to prevent anemia and iron deficiency. This study was registered at www.crd.york.ac.uk/PROSPERO as CRD42020156663. **Keywords:** anemia, iron deficiency, micronutrient status, child undernutrition, complementary feeding, nutrient supplements, home fortification

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

Micronutrient deficiencies are estimated to affect two billion people globally (1, 2) and roughly one-third of the world's population is anemic (3). Infants and young children in low- and middle-income countries are particularly vulnerable to micronutrient undernutrition, owing in part to low micronutrient stores at birth, inadequate dietary intake of bioavailable micronutrients, and increased micronutrient requirements due to infection or malabsorption (4, 5). Deficiencies of iron, zinc, and vitamin A in these populations are associated with increased morbidity and mortality and delayed psychomotor and neurocognitive development (1). Nutritional strategies to prevent micronutrient deficiencies include dietary diversification and modification, provision of supplements, fortification (i.e. large-scale food fortification, biofortification and targeted in-home fortification), and supplemental feeding (e.g., fortified blended foods and lipid-based nutrient supplements). Small-quantity lipid-based nutrient supplements (SQ-LNS) have been designed to prevent malnutrition and provide multiple micronutrients embedded in a food base that also provides energy (100-120 kcal/d), protein and essential fatty acids. This combination of macro- and micro-nutrients in SQ-LNS has the potential to address multiple nutritional deficiencies simultaneously, thus reducing undernutrition (6). A 2019 Cochrane Systematic Review and meta-analysis showed that SQ- and mediumquantity LNS (MQ-LNS) (~125 – 250 kcal/d) given during the period of complementary feeding (6-24 months) significantly reduced the prevalence of anemia by 21% (RR 0.79, 95% CI 0.69 to 0.90; 5 studies; anemia as defined by trialists) compared to no intervention (7). Similarly, a 2020 meta-analysis demonstrated a 16% reduction in the prevalence of anemia (RR 0.84, 95% CI 0.75,

0.93; 8 studies; anemia as defined by trialists) among children who received SQ- or MQ-LNS in

comparison to a control group (8). To-date, no meta-analysis has assessed the impact of SQ-LNS

provided during the period of complementary feeding on the micronutrient status of infants and young children. However, individual studies have demonstrated significant reductions in the prevalence of iron deficiency and iron deficiency anemia (9-16), although there is heterogeneity in the magnitude of effects. Some, but not all, studies have shown significant improvements in vitamin A, B12 and folate status (11-13, 15, 17); no studies have reported an effect of SQ-LNS on zinc status (9, 11, 15).

Differences in study design and context and characteristics of study participants may modify the effect of SQ-LNS on anemia and biomarkers of micronutrient status. The identification of subgroups of infants and young children who experience greater benefits from SQ-LNS, or who are more likely to respond to the intervention, is useful in informing the development of public health policies and programs (18). Thus, we conducted an individual participant data (IPD) meta-analysis of randomized controlled trials (RCTs) of SQ-LNS provided to infants and young children 6 to 24 months of age. The objectives of this analysis were to (1) generate pooled estimates of the effects of SQ-LNS provided to infants and young children 6 to 24 months of age on hemoglobin concentration and selected biomarkers of micronutrient status, and (2) identify study- and individual-level modifiers of the effect of SQ-LNS on these outcomes in the same populations. Two companion articles report results for other outcome domains, growth (19) and development (20), from the same IPD meta-analysis.

Methods

Methods broadly followed those presented in a companion article (19). This systematic review and IPD meta-analysis was pre-registered through PROSPERO (CRD42020156663) (21). A detailed protocol and statistical analysis plan were developed prior to analyses and are

available online (22), and we have reported results according to PRISMA-IPD guidelines (23). The analyses were approved by the institutional review board of the University of California, Davis (1463609-1). All individual trial protocols were approved by their relevant institutional ethics committees.

Inclusion and exclusion criteria for this systematic review and IPD meta-analysis

Trials were eligible for inclusion if they were individual or cluster RCTs with either longitudinal follow-up or repeated cross-sectional data collection, were conducted in low- or middle-income countries (24), provided SQ-LNS (< ~125 kcal/d) to study participants for at least three months during any part of the age range between 6-24 months of age, and reported at least one outcome of interest.

We excluded trials in which SQ-LNS was used for the treatment, not prevention, of malnutrition (i.e., only children with moderate to severe malnutrition were eligible to participate), as well as studies specifically conducted in hospitalized populations or among children with a pre-existing disease. Trials were excluded if the only available comparison group received other types of non-LNS child supplementation (e.g., multiple micronutrient powder, fortified blended food) or if SQ-LNS provision was combined with an additional supplemental food or nutrients within a single arm (e.g., SQ-LNS + food rations vs. control), and there was no appropriate comparison group that would allow isolation of the SQ-LNS effect (e.g., food rations alone).

Trials in which there were multiple relevant SQ-LNS interventions (e.g., varying dosages or formulations of SQ-LNS in different arms), or that combined provision of SQ-LNS with other non-nutritional interventions (e.g., water, sanitation and hygiene (WASH)), were eligible for

inclusion. In such trials, all arms that provided SQ-LNS were combined into one group, and all non-LNS arms were combined into a single comparison group for each trial (herein labeled "Control"), excluding intervention arms that received non-LNS child supplementation (e.g., multiple micronutrient powder, fortified-blended food). We also conducted a sensitivity analysis restricting the comparison to specified contrasts of intervention arms within multiple intervention trials (see below).

Individual children were included in the analyses if their age at baseline allowed them to receive at least three months of intervention (supplementation or control group components) between 6 and 24 months of age, and if biochemical outcome assessment occurred within 3 months of the intended, trial-defined end of supplementation.

Search methods and identification of studies

We identified potential studies for inclusion in the IPD analysis from a recent systematic review and meta-analysis of LNS (7). We then repeated the database search strategy employed by Das *et al.*(7), using the same keyword and controlled vocabulary search terms, to capture additional studies (both completed and on-going) indexed in one of 23 international or regional electronic databases and 2 trial registers between July 1, 2018 and May 1, 2019 (*see Supplemental Methods*). One of the authors (KRW) reviewed the titles and abstracts of all studies included in the 2019 Cochrane review, as well as the additional studies identified by the repeated search strategy, to select all potentially relevant studies for full text review. The full-text reports of all potentially relevant records were reviewed. Trials were assessed against the inclusion and exclusion criteria detailed above. In September 2019, the same author reviewed the previously identified on-going studies that met inclusion and exclusion criteria to determine if results for outcomes of interest had been subsequently published.

Data collection and harmonization

We invited all principal investigators of eligible studies to participate in this IPD metaanalysis. Individual investigators were asked to provide de-identified individual participant data
(primary data) for pre-specified variables (defined above and detailed in a data dictionary
provided to investigators). The IPD analyst (CDA) collected and managed the individual
participant data, and communicated with investigators to request any missing variables or other
information.

IPD integrity

We conducted a complete-case, intention to treat analysis (25). We checked data for completeness by crosschecking sample sizes with study protocols and publications. We also crosschecked the data provided against reported values for each trial to ensure consistency. Variables were assessed for outliers and low frequency categories. Relevant model assumptions were assessed (e.g. Shapiro-Wilk normality testing and Breusch-Pagan heteroscedasticity testing) and outcome variables were appropriately transformed before subsequent analyses, as necessary.

Assessment of risk of bias in each study and quality of evidence across studies

Two independent reviewers (KRW and CDA) assessed risk of bias using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (26). We assessed each trial against the following criteria: random sequence generation and allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective

reporting (reporting bias), and other sources of bias. Reviewers also assessed the quality of evidence for each primary and secondary outcome across all trials based on the five GRADE criteria: risk of bias, inconsistency of effect, imprecision, indirectness and publication bias (27). Any discrepancies were resolved by discussion or consultation with the core working group, as needed.

Specification of outcomes and effect measures

We specified outcomes *a priori* in the statistical analysis plan (22). Outcomes of interest are listed in **Box 1**. For the estimation of the main effects, we pre-specified hemoglobin concentration, anemia, moderate-to-severe anemia, and biomarkers of iron status as primary outcomes in the statistical analysis plan, and present results for all outcomes. Hemoglobin concentrations were adjusted for altitude, as necessary (28). Ferritin, sTfR, ZPP, zinc, retinol and RBP concentrations were adjusted for inflammation (i.e., C-reactive protein (CRP) and/or α-1-acid glycoprotein (AGP) concentrations, as available), using a regression correction approach adapted from the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project and described in detail elsewhere (29); results are presented for inflammation-adjusted concentrations.

The principal measure of effect for normally distributed continuous outcomes was the mean difference (MD) between the intervention and comparison groups at endline, defined as the principal post-intervention time point as reported by each longitudinal trial or at an age closest to the end of the supplementation period for cross-sectional samples. For natural log transformed outcomes, the principal measure of effect was the ratio of geometric means (GMR) between the two groups at endline. For binary outcomes, the principal measure of effect was the prevalence ratio (PR; relative difference in proportions between groups) at endline. We also estimated

prevalence differences (PD; in absolute percentage points) but considered them as secondary assessments of binary outcomes because such estimates are less consistent than prevalence ratios (26).

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

The treatment comparison of interest was child SQ-LNS vs. control. In the intervention groups, child SQ-LNS may have been provided along with other nutrition-sensitive cointerventions (e.g., WASH or child morbidity monitoring and treatment). The control groups consisted of passive or active comparison arms which provided no intervention or an intervention without any type of LNS or other child supplement (e.g., WASH). Several trials (or arms within trials) have delivered SQ-LNS to children whose mothers received maternal SQ-LNS during pregnancy and postpartum. We had originally planned to include trial arms that provided both maternal and child SQ-LNS in a sensitivity analysis only (i.e., the all-trials analysis), as maternal supplementation may have an additive effect on child outcomes when SO-LNS is provided to both mothers and to their children. However, to maximize study inclusion and participant sample size, we decided post-hoc that if the main effects did not differ between the child-LNS-only analysis and the all-trials analysis (including maternal plus child LNS arms) by more than 20% for mean differences or by more than 0.05 for ratios of geometric means or prevalence ratios, the results of the all-trials analyses would be presented as the principal findings. Two additional sensitivity analyses were also conducted, as described below.

Synthesis methods and exploration of variation in effects

We separately investigated: 1) full sample main effects of the intervention, 2) effect modification by study-level characteristics, and 3) effect modification by individual-level characteristics. For all three sets of analyses, we used a two-stage approach, which is preferred when the analysis includes cluster-randomized trials (30). In the first stage, we generated

intervention effect estimates within each individual study. For longitudinal studies, we controlled for baseline status of the outcome variable, if available, to gain efficiency. For cluster-randomized trials, we used robust standard errors with randomization clusters as the independent unit (31). In the second stage, we pooled the first stage estimates using inverse-variance weighted fixed effects. We also conducted sensitivity analyses in which we pooled estimates using inverse-variance weighted random effects (32). Pooled estimates were only generated if three or more study or sub-study SQ-LNS vs. control comparisons were available for inclusion in the pooled estimate (e.g., 3 or more comparisons were represented within a study-level effect modification category).

- 1) Full sample main effects of the intervention: We first estimated the intervention effect for each study. We then pooled the first stage estimates to generate a pooled point estimate, 95% confidence interval, and corresponding p-value.
- 2) Effect modification by study level characteristics: We identified potential study-level effect modifiers prior to receipt of data, and categorized individual studies based on the distribution of effect modifier values across all studies (**Box 2**). We used random effects meta-regression to test the association between each effect modifier and the intervention. In the first stage of analysis, we estimated the parameter corresponding to the intervention effect as described above. In the second stage, we used a bivariate random effects meta-regression to test the association between the study-specific intervention effect and study level characteristics.
- 3) Effect modification by individual level characteristics: We identified potential individual-level characteristics based on a comprehensive review of effect modifiers considered by individual trials (either listed *a priori* in statistical analysis plans or as published) or selected based on biological plausibility (Box 2). We estimated the parameter corresponding to the

interaction term of the effect modifier and the intervention for each study (31), as follows. For categorical effect modifiers, we first recoded them to create binary variables if needed, and then determined the interaction between the intervention and the binary effect modifier. We transformed continuous effect modifiers into binary variables by modeling the relationship within each study using splines and then pooling the first stage estimates to generate a pooled, fitted line. We defined programmatically useful dichotomous cutoffs based on the pooled fitted spline results and relevant context. We then generated pooled intervention effect estimates within each category to determine how the intervention effect in one subgroup differed from the intervention effect in the specified reference subgroup.

In all analyses, heterogeneity was assessed using I^2 and Tau^2 statistics, within strata when relevant (33). We used a p-value of < 0.05 for main effects and a p-diff or p-for-interaction < 0.10 for effect modification by study-level or individual-level characteristics, respectively. Because biochemical outcomes are inter-related and the effect modification analyses are inherently exploratory, we did not adjust for multiple hypothesis testing (34).

To aid in interpretation of individual-level effect modification, we evaluated the results for binary outcomes to identify what we will call the "cutoff effect". The distribution of the continuous outcome relative to the cutoff for the corresponding binary outcome (e.g., distribution of hemoglobin around the 110 g/L anemia cutoff) in the 2 effect modifier subgroups can influence the prevalence ratio and prevalence difference. When the mean in each of the 2 subgroups falls in a different location relative to the cutoff, the proportion of children close to the cutoff may be different between subgroups. This can lead to a greater reduction in the adverse binary outcome within one subgroup than within the other even if the shift in the mean value due to SQ-LNS is the same in both subgroups. To examine this, we simulated what would happen if

we shifted the distribution of the non-reference effect modification subgroup to align with the reference subgroup (see Box 2), while maintaining the observed intervention effect mean difference in the continuous outcome within each subgroup. Based on ad-hoc, pragmatic criteria, if the p-for-interaction shifted from < 0.1 to > 0.2, we concluded that the cutoff effect explained the apparent effect modification; if it shifted from < 0.1 to > 0.1 but < 0.2, we concluded that the cutoff effect partially contributed to the apparent effect modification.

Additional sensitivity analyses

For the child SQ-LNS only and all-trials analyses, we combined all non-LNS arms into a 'Control' group for that trial. However, substantial variations in trial design (e.g., integration of SQ-LNS supplementation with WASH interventions or enhanced morbidity monitoring and treatment, use of passive vs. active control arms) might influence the effect size of the estimates. Therefore, we conducted sensitivity analyses based on child-LNS only analyses in which we (1) separated the comparisons within trials that contained multi-component arms, thus restricting the comparisons to pairs of arms with the same non-nutrition components (e.g. SQ-LNS+WASH vs. WASH and SQ-LNS vs. control) or (2) excluded passive control arms, i.e., restricting the comparison to SQ-LNS vs. active control arms (Supplemental Table 1). These analyses are considered exploratory.

Results

Literature search and trial characteristics

We identified 15 trials that met our inclusion criteria for the child SQ-LNS only and/or all-trials analyses, 13 of which (35-48) provided individual participant biochemical data and are included in this analysis (9-13, 15-17, 39, 46-48) (**Figure 1**). In one study biochemical data were

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

not collected (49), and investigators for one trial were unable to participate (14). An overview of each trial included in the analysis is provided in **Table 1**; additional details are provided in Supplemental Table 1. One trial was designed a priori to present results separately for HIV exposed and HIV un-exposed children (47, 48); therefore we considered it herein as two comparisons in all analyses and presentation of results. The PROMIS trials in Burkina Faso and Mali each included a longitudinal cohort and repeated cross-sectional surveys (at baseline and endline); however biochemical samples were collected only in the cross-sectional surveys (39, 46). The 13 trials in these analyses were conducted in 9 countries in Sub-Saharan Africa and South Asia, and included a total of 15,946 infants and young children with biochemical data. Eleven trials began child supplementation with SQ-LNS at 6 months of age; for the remaining two trials, SQ-LNS supplementation began when infants were 9 months of age in one (38), and between 6-11 months of age in the other (43). Supplementation occurred for 6 to 18 months in duration, depending on the trial. Four trials included intervention arms that also provided SQ-LNS to mothers during pregnancy and the first 6 months postpartum (36, 41, 43, 44). The majority of trials provided a peanut- and milk-based SQ-LNS providing approximately 120 kcal/d and 1 RDA of most micronutrients (Supplemental Table 2). However, the iron dose per day varied among trials. Four trials provided 9 mg/d iron (36, 37, 40, 42), 8 trials provided 6 mg/d iron (38, 39, 41, 43-48), and one trial provided 3.3 – 9 mg/d iron depending on study arm and child age (35). Categorizations and descriptive information for potential study- and individual-level effect modifiers, by trial, are presented in **Supplemental Tables 3 - 4**, respectively.

Characteristics ranged widely across trials. Based on data from national surveys, the prevalence

of anemia among children 6-59 months ranged from 36% to 88%, and the prevalence of malaria (presumed and confirmed cases) ranged from < 1% to 59% (50). Based on data from individual trials, the study-level prevalence of elevated CRP ranged from 11% to 34% and the prevalence of elevated AGP ranged from 29% to 68%.

All trials measured hemoglobin concentration (n = 15,398), and 11 reported at least one biomarker of iron status (n = 1,542 – 3,078) (Supplemental Table 1, **Supplemental Table 5**). Fewer studies assessed zinc (3 studies; n = 1,133) or vitamin A (9 studies; n = 1,236 – 2,314) status. Assessments of hepcidin, folate and vitamin B12 concentrations were planned in 3-4 studies each, but data were not yet available from a sufficient number of trials to be included in the present analysis. Median biomarker concentrations and prevalence of dichotomous study outcomes among control groups by trial are presented in Table 1 (anemia and iron deficiency) and **Supplemental Table 6** (all outcomes). In control groups at endline, the prevalence of anemia ranged from 16% to 91%, the prevalence of iron deficiency ranged from 22% to 59%, and the prevalence of IDA ranged from 9% to 55%.

In general, trials were considered to have a low risk of bias, with the exception of lack of masking of participants owing to the nature of the intervention (**Supplemental Table 7** and **Supplemental Figure 1**).

Main effects of SQ-LNS on anemia and micronutrient status

Results from the all-trials analyses, inclusive of maternal + child SQ-LNS trials/arms, are presented below, and in **Table 2**, because the results from the all-trials and child-LNS-only analyses were similar for all outcomes (**Supplemental Figures 2A to 2D**). Forest plots for all main effects by outcome and individual study are presented below for selected outcomes and as supplemental materials for all other outcomes (**Supplemental Figures 3A to 3AA**).

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

SO-LNS had a significant positive effect on all biomarkers of hematological and iron status (Table 2, Figures 2-3). Compared to control children, hemoglobin concentrations were 2.77 g/L higher among children who received SQ-LNS; additionally, ferritin concentrations were 56% higher, and sTfR and ZPP concentrations were 17% lower among children who received SQ-LNS vs. control. SQ-LNS reduced the prevalence of anemia by 16% (10 percentage points), iron deficiency by 56% (22 percentage points), and IDA by 64% (14 percentage points). Differences in plasma zinc and retinol concentrations between those who received SQ-LNS and those who did not were not significant. RBP concentrations were 7% higher among children who received SQ-LNS compared to the control group. SQ-LNS reduced the prevalences of low and marginal vitamin A status, as measured by RBP, by 56% (3 percentage points) and 22% (8 percentage points), respectively; there was no effect of SQ-LNS on vitamin A status as measured by retinol. We rated the quality of evidence for hemoglobin, ferritin and sTfR concentrations, as well as anemia, moderate-to-severe anemia, iron deficiency, elevated sTfR and IDA as high, based on the GRADE criteria listed above in Methods: at least 6 randomized controlled trials were available for these outcomes and the total sample size was \sim 2,500, the risk of bias was low, all trials were directly aimed at evaluating SQ-LNS, funnel plots revealed no indication of publication bias, and the direction of the effect was consistent even though the magnitude of the effect across trials differed (i.e., moderate to high heterogeneity). For all other outcomes, we rated the quality of the evidence as low to moderate, primarily because of limited availability of data, i.e. fewer trials and participants. Mean differences, ratios of geometric means and prevalence ratios for all outcomes were either identical or greater in random vs. fixed effects models (Supplemental Figures 3A to 3AA). The point estimates of the main effects were similar in the sensitivity analyses in which multicomponent arms (e.g. WASH + SQ-LNS) were compared to reference groups that had the same components without SQ-LNS and in which passive control trials were excluded (Supplemental Figures 2A-D). For example, the prevalence ratios for anemia ranged from 0.82-0.84 and those for iron deficiency were 0.36-0.44. There were no differences in statistical significance between models in which outcomes were adjusted vs. not adjusted for inflammation (data not shown).

Effect modification by study-level characteristics

The effects of SQ-LNS on hemoglobin, anemia and biomarkers of iron status, stratified by study-level characteristics, are presented in **Figures 4A to 4H**, and an overview of these results is presented in **Table 3**. Forest plots for all outcomes stratified by study-level effect modifiers are presented in **Supplemental Figures 4A to 4AA**. We were unable to generate pooled estimates for effect modification by any study-level characteristics for ZPP and biomarkers of zinc and vitamin A status (i.e., retinol and RBP) due to the limited number of studies that measured these biomarkers. For iron status biomarkers (ferritin and sTfR), water quality and sanitation sub-groups captured the same trials, so these characteristics are considered as a single effect modifier at the study-level. Effect modification results were generally consistent across all sensitivity analyses (**Supplemental Figures 5A to 5AA**) and between models in which outcomes were inflammation-adjusted or not (data not shown); the results presented below refer to the all-trials analyses of inflammation-adjusted outcomes.

In all analyses of effect modification by study-level characteristics, the 95% confidence interval of the mean hemoglobin difference, and the ratios of geometric mean ferritin and sTfR concentrations, excluded the null for both strata, indicating that there were significant improvements in hemoglobin, ferritin and sTfR concentrations among children receiving SQ-LNS regardless of study-level characteristics. Similarly, the upper bound of the 95% confidence

interval was < 1 for the prevalence ratio and < 0 for the prevalence difference for both categories in all comparisons, indicating that there were significant reductions in the prevalence of anemia, iron deficiency and IDA among children receiving SQ-LNS regardless of study-level characteristics. However, there were some significant interactions, which are described below.

Hemoglobin concentrations and anemia

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

Reductions in anemia prevalence due to SQ-LNS were greater among studies conducted in South Asia than in Africa (PR: 0.64 vs. 0.81, Figure 4B, Supplemental Figure 4B1). We observed a greater effect of SQ-LNS on hemoglobin concentrations among high anemia burden countries, compared to countries with a moderate burden of anemia (MD: 4.88 g/L vs. 2.49 g/L, Figure 4A, Supplemental Figure 4A2), although the effect of SQ-LNS on anemia prevalence was lower in high anemia burden countries than in moderate anemia burden countries (PR: 0.83 vs. 0.75, Figure 4B, Supplemental Figure 4B2). In addition, there was a greater effect of SQ-LNS on the prevalence of anemia among studies conducted in countries with a low vs. high malaria prevalence (PR: 0.73 vs. 0.84, Figure 4B, Supplemental Figure 4B3) and at sites with a low inflammation prevalence compared to those with a higher inflammation prevalence (PR: 0.71 vs. 0.87, Figure 4B, Supplemental Figure 4B4). Study-level access to improved sanitation or water quality did not significantly modify the effects of SQ-LNS on hemoglobin concentrations (Figure 4A, Supplemental Figures 4A4 and 4A5) or the prevalence of anemia (Figure 4B, Supplemental Figures 4B4 and 4B5). Among studies that provided supplements for longer than 12 months compared to 12 months or less, there was a greater effect of SQ-LNS on the prevalence of both anemia (PR: 0.69

vs. 0.83, Figure 4B, Supplemental Figure 4B7) and moderate-to-severe anemia (PR: 0.62 vs.

0.74, Figure 4C and Supplemental Figure 4D7). Similarly, among studies that provided a higher iron dose (9 mg/d) compared to those providing a lower dose (< 9 mg/d), we observed a greater effect of SQ-LNS on the prevalence of anemia (PR: 0.61 vs. 0.85, Figure 4B, Supplemental Figure 4B8) and moderate-to-severe anemia (PR: 0.52 vs. 0.76, Supplemental Figure 4D8). There was no effect modification by frequency of contact (weekly vs. monthly), but we did observe a greater effect of SQ-LNS on hemoglobin concentrations and the prevalence of anemia among studies that reported high compliance, compared to those reporting lower compliance (MD: 4.78 g/L vs. 2.59 g/L, Figure 4A and Supplemental Figure 4A10 and PR: 0.68 vs. 0.84, Figure 4B and Supplemental Figure 4B10, respectively).

Biomarkers of iron status and prevalence of deficiency

The effect of SQ-LNS on the prevalence of iron deficiency (inflammation-adjusted ferritin concentration < $12~\mu g/L$) was greater among trials conducted in South Asia than in Africa (PR: 0.31 vs. 0.49, Figure 4E and Supplemental Figure 4G1), although the percentage point reduction in iron deficiency associated with SQ-LNS was lower among sites in South Asia (vs. Africa) (18 vs. 30 percentage points; P = 0.026, Supplemental Figure 4H1). Study level sanitation and water quality did not significantly modify the effects of SQ-LNS on ferritin or sTfR concentrations or the relative reductions in the prevalences of iron deficiency and high sTfR (Figures 4D-4E, 4G-4H, Supplemental Figures 4F5-6, 4G5-6, 4K5-6, 4L5-6). We did observe greater effects of SQ-LNS on the relative reduction in the prevalence of IDA among trials conducted in sites where a greater proportion of households had access to improved sanitation and water quality, compared to sites with lower sanitation and water quality (PR: 0.20 vs. 0.43, Figure 2F, Supplemental Figure 4I5-6), consistent with the non-significant differences

in the relative reductions in the prevalence of iron deficiency (PR: 0.38 vs. 0.51; P-for-diff = 0.105, Figure 4E, Supplemental Figure 4G6). However, the percentage point reduction in iron deficiency due to SQ-LNS was actually greater among trials conducted in sites where a lower (vs. higher) proportion of households had access to improved sanitation and water quality (28 vs. 18 percentage points; P-for-diff = 0.006, Supplemental Figures 4H5-6).

We observed a greater effect of SQ-LNS on the prevalence of iron deficiency among studies that provided SQ-LNS for longer than 12 months compared to studies of shorter durations (PR: 0.34 vs. 0.49, Figure 4E, Supplemental Figure 4G7). In addition, we observed a greater effect of SQ-LNS on ferritin concentrations among studies that provided 9 mg/d of iron, compared to studies that provided < 9 mg/d (GMR: 1.67 vs. 1.42, Figure 4D and Supplemental Figure 4F8). Frequency of contact did not significantly modify the effects of SQ-LNS on ferritin or sTfR concentrations, nor on prevalences of iron deficiency or IDA. However, the effect of SQ-LNS on elevated sTfR (indicative of impaired functional iron status) was greater among studies in which children received weekly vs. monthly study visits (PR: 0.46 vs. 0.69, Figure 4H and Supplemental Figure 4L9).

Overview of study-level effect modification

Table 3 shows that numerous characteristics of study context and design (e.g., anemia burden, iron dose, duration of supplementation) modified the effect of SQ-LNS on hematological and iron status biomarkers. When there is no significant effect modification for a continuous outcome (e.g., hemoglobin concentration) but there is for the prevalence ratio or prevalence difference for the corresponding binary outcome (e.g. anemia), the results could be due to the "cutoff effect", as described in Methods. Our simulations identified several cutoff effects (Table

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

3). For example, we observed greater effects of SO-LNS on the prevalence of anemia in sites with a moderate (vs. high) burden of anemia, a low (vs. high) malaria burden, and a low (vs. high) inflammation burden, three study-level characteristics that tended to cluster together. However, the effects of SQ-LNS on hemoglobin concentrations were greater in studies with a higher burden of anemia and mean hemoglobin differences due to SO-LNS did not differ significantly by malaria or inflammation burden. Simulations indicated that the observed effect modification by study-level anemia, malaria and inflammation burden with respect to the prevalence ratio for anemia appears to be due to the cut-off effect (i.e., differences in the population distribution of hemoglobin between sub-groups). Among control group children, mean hemoglobin concentrations were higher in sites with lower burdens of anemia, malaria and inflammation than in sites with higher prevalences of these factors (≈ 114 g/L vs. ≈ 100 g/L). As a result, a greater proportion of children who received SO-LNS shifted across the cut-off from anemic to non-anemic in the former sites than in the latter. The cutoff effect also appeared to contribute, at least partially, to the apparent effect modification by a) region, for the prevalence of anemia and the prevalence difference for iron deficiency, b) improved sanitation and water quality, for the prevalence of IDA, c) supplementation duration and iron dose, for the prevalence of moderate-to-severe anemia, and d) frequency of contact, for the prevalence of elevated sTfR. Effect modification by individual-level characteristics The effects of SQ-LNS on hemoglobin (anemia) and biomarkers of iron status, stratified by individual-level (i.e., child, maternal and household) characteristics, are presented in Figures **5A-5H** and an overview of individual-level effect modification is provided in **Table 4.** Forest plots of all outcomes by potential individual-level effect modifiers are presented in

Supplemental Figures 6A to 6AA and 7A to 7AA. For some biomarkers of micronutrient

status, we were unable to generate pooled estimates for effect modification by certain potential individual-level effect modifiers because fewer than three trials (comparisons) assessed both the outcome and the effect modifier of interest and/or there were too few individuals with the outcome categorized into each stratum (e.g., ferritin concentration by baseline anemia status or household sanitation). Effect modification results were generally consistent across all sensitivity analyses and between the fixed and random effects models (Supplemental Figures 8A to 8AA). Because all-trials analyses maximized the sample size, some potential effect modifiers were significant in the all-trials, but not in the sensitivity analyses. However, the directionality of effect modification was consistent across all analyses. In addition, results were generally consistent between models in which outcomes were inflammation-adjusted or not (data not shown). Thus, the results presented below refer to the fixed effects models for all-trials analyses of inflammation-adjusted outcomes.

Hemoglobin concentration and prevalence of anemia

In general, maternal characteristics did not significantly modify the effect of SQ-LNS on hemoglobin concentration or anemia, with two exceptions: there was a greater absolute reduction in the prevalence of moderate-to-severe anemia (8 vs. 6 percentage points, P-for-interaction = 0.047; Supplemental Figure 6E1) among children of mothers with a higher (vs. lower) BMI, and there was a greater effect of SQ-LNS on hemoglobin concentration and anemia prevalence among children of older compared to younger mothers (MD: 3.33 g/L vs. 2.61 g/L and PR: 0.83 vs. 0.87, respectively; Figures 5A-B, Supplemental Figures 6A2 and 6B2).

Regarding child characteristics, SQ-LNS had a greater effect among later-born vs. first-born children on hemoglobin concentrations (MD: 3.25 g/L vs. 2.28 g/L; Figure 5A, Supplemental Figure 6A5) and the percentage point reduction in the prevalence of anemia (12)

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

vs. 7 percentage points; P-for-interaction = 0.024, Supplemental Figure 6C5), although not on the relative reduction in anemia prevalence (Figure 5B, Supplemental Figure 6B5). The effect of SQ-LNS on hemoglobin concentration did not differ by child sex (Figure 5A, Supplemental Figure 6A4) but we observed a greater effect of SQ-LNS on the prevalence of anemia among female vs. male children (PR: 0.82 vs. 0.87; Figure 5B, Supplemental Figure 6B4). SQ-LNS had a greater effect on hemoglobin concentrations, but not the prevalence of anemia, among children who were anemic at baseline (vs. those who were not) (MD: 3.91 g/L vs. 1.63 g/L; Figures 5A and 5B, Supplemental Figures 6A7 and 6B7). The effect of SQ-LNS on hemoglobin concentration did not differ by inflammation status at endline (Figure 5A, Supplemental Figure 6A9), however, SQ-LNS had a greater effect on the prevalence of anemia among children without (vs. with) inflammation at endline (PR: 0.66 vs. 0.85; Figure 5B, Supplemental Figure 6B9). Child acute malnutrition at baseline and receipt of high-dose vitamin A supplements did not significantly modify the effects of SQ-LNS on hemoglobin concentrations or the prevalence of anemia. Household water quality and sanitation did not significantly modify the effects of SQ-LNS on hemoglobin concentrations (Figure 5A, Supplemental Figure 7A3-4). However, there was a greater effect of SQ-LNS on anemia prevalence among children in households with improved water quality than among children in households with unimproved water quality (PR: 0.82 vs. 0.88; Figure 5B, Supplemental Figure 7B3). Conversely, the effects of SQ-LNS on prevalences of anemia and moderate to severe anemia were greater among children in households with unimproved vs. improved sanitation (Figure 5B-C, Supplemental Figures 7B4

and 7D4). Socio-economic status (SES), food security, and season of outcome measurement did

not significantly modify the effects of SQ-LNS on hemoglobin concentrations or the prevalence of anemia.

Biomarkers of iron status and prevalence of iron deficiency and iron deficiency anemia

In general, maternal characteristics (i.e., BMI, age and education) did not significantly modify the effect of SQ-LNS on iron status biomarkers (i.e., ferritin, sTfR or ZPP), with the exception of a greater absolute reduction in the prevalence of IDA (21 vs. 13 percentage points, P-for-interaction = 0.023; Supplemental Figure 6J1) among children of mothers with a higher (vs. lower) BMI, and greater absolute reductions in the prevalence of elevated ZPP among children of mothers with more (vs. less) formal education (14 vs. 9 percentage points, P-for-interaction = 0.080; Supplemental Figure 6P3).

We observed a greater effect of SQ-LNS on ferritin concentrations among later-born children, compared to first-born children (GMR: 1.64 vs. 1.40; Figure 5D and Supplemental Figure 6F5), among children who were acutely malnourished (vs. non-malnourished) at baseline (GMR: 1.85 vs. 1.47; Figure 5D and Supplemental Figure 6F6), and among children without (vs. with) inflammation at endline (GMR: 1.65 vs. 1.48; Figure 5D and Supplemental Figure 6F9). In addition, we observed a greater effect of SQ-LNS on ZPP concentrations in male vs. female children (GMR: 0.76 vs. 0.82; Supplemental Figure 6N4). No individual-level child characteristics modified the effect of SQ-LNS on the prevalence of iron deficiency, elevated sTfR or ZPP, or IDA.

Household characteristics (i.e., SES, food security, water quality and sanitation) did not modify the effect of SQ-LNS on ferritin or ZPP concentrations or the prevalence of iron deficiency, elevated ZPP or IDA, with the exception of greater absolute reductions in the

prevalence of IDA among children of higher (vs. lower) SES (20 vs. 12 percentage points, P-forinteraction = 0.039; Supplemental Figure 7J1). We observed a greater effect of SQ-LNS on the
prevalence of elevated sTfR among children in households with SES above (vs. below) the
study-specific median (PR: 0.60 vs. 0.71; Figure 5H, Supplemental Figure 7L1). In addition, SQLNS had a greater effect on sTfR concentrations among children in households with improved
(vs. unimproved) water quality (GMR: 0.75 vs. 0.82; Figure 5G, Supplemental Figure 7K3).

There was a greater effect of SQ-LNS on ferritin concentrations, and the prevalence of
iron deficiency, in the rainy season than in the dry season (GMR: 1.74 vs. 1.44; PR: 0.37 vs.
0.53; Figure 5D-E, Supplemental Figures 7F6, 7G6). In addition, there was a greater effect of
SQ-LNS on ZPP concentrations in the rainy season vs. the dry season, (GMR: 0.76 vs. 0.84;

Biomarkers of zinc and vitamin A status

Supplemental Figure 7N6).

The effect of SQ-LNS on plasma zinc concentrations was greater among children of older vs. younger mothers (GMR: 1.03 vs. 0.96; Supplemental Figure 6Q2), and in the rainy season as compared to the dry season (GMR: 1.02 vs. 0.99; Supplemental Figure 7Q6). However, there was no main effect of SQ-LNS on plasma zinc concentrations, and in both aforementioned cases of effect modification, the confidence intervals around the estimates in both sub-groups included one; therefore, it is likely that there was no true effect on plasma zinc concentration in either sub-group. No other maternal, child or household characteristics significantly modified the effect of SQ-LNS on plasma zinc concentrations.

Maternal characteristics did not modify the effect of SQ-LNS on vitamin A status. There was a greater effect of SQ-LNS on RBP concentrations among children with (vs. without)

inflammation at endline (GMR: 1.10 vs. 1.04; Supplemental Figure 6W9). There was also a greater effect of SQ-LNS on the prevalence of marginal vitamin A status (RBP < 1.05 μ mol/L) among children in households with higher (vs. lower) SES (PR: 0.70 vs. 0.87; Supplemental Figure 7Z1). In addition, we observed a greater effect of SQ-LNS on retinol concentrations among children who were acutely malnourished (vs. non-malnourished) at baseline (GMR: 1.14 vs. 1.02; Supplemental Figure 6R6) and among children in mildly insecure or food secure (vs. moderately to severely food insecure) households (GMR: 1.06 vs. 0.99; Supplemental Figure 7R2), although there was no main effect of SQ-LNS on plasma retinol concentrations.

Overview of individual-level effect modification

Table 4 and **Supplemental Table 8** show that some characteristics (e.g., birth order, household water quality and sanitation, season and child inflammation) modified the effect of SQ-LNS on a number of hematological and iron status biomarkers while others (e.g., maternal education, child sex, child anemia at baseline, high-dose vitamin A supplementation, and household food security) exhibited effect modification for only a few outcomes.

The results of the simulations to identify cutoff effects are indicated in Table 4 and Supplemental Table 8. For example, among children who received SQ-LNS vs. control, the prevalence of anemia was reduced by 18% among females and by 13% among males. However, there was no significant effect modification for the continuous outcome (i.e., hemoglobin concentration). Mean hemoglobin concentrations in the control group at endline were greater among females than males (107 g/L vs. 105 g/L) and effect modification by sex became non-significant for anemia prevalence in the simulation models; therefore, the cut-off effect is the most likely explanation for these findings. The cut-off effect appeared to explain effect modification by maternal BMI, with regard to the prevalence difference for IDA, and by

maternal education with regard to the prevalence difference for elevated ZPP. For the prevalence of elevated sTfR (ratio and difference), the cutoff effect appeared to explain effect modification by SES. The cutoff effect also appeared to contribute, at least partially, to the apparent effect modification by sanitation for relative anemia prevalence (but not the prevalence difference for anemia, nor the prevalence ratio or prevalence difference for moderate-to-severe anemia).

For maternal age, however, there was significant effect modification for hemoglobin concentrations and both the prevalence ratio and prevalence difference for anemia, so this was not due to the cutoff effect. In addition, the cutoff effect did not explain effect modification for anemia by maternal BMI, birth order, inflammation or water quality, for iron deficiency by season of outcome assessment, or for IDA and vitamin A deficiency by SES.

Discussion

This individual participant data analysis included 13 RCTs in nine different countries with a total sample size of ~15,000 children. SQ-LNS substantially reduced the prevalence of anemia, moderate-to-severe anemia, iron deficiency, and IDA among infants and young children who received SQ-LNS for 3-18 months, relative to control children. The beneficial effects of SQ-LNS on hemoglobin appeared to be greater among studies that were conducted in countries with a high burden of anemia (>60%); greater beneficial effects of SQ-LNS on anemia and iron status were observed among studies that provided SQ-LNS with a higher dose of iron and for a longer duration. Several of the individual-level characteristics also appeared to modify the effects of SQ-LNS on anemia and iron status. However, even when the magnitude of effect differed between sub-groups, the magnitude of the modifying effects was generally small and we observed positive effects of SQ-LNS within all sub-groups, indicating the potential of SQ-LNS

to provide benefits across a range of individual, population and study design characteristics. This was also the case for the growth (19) and development (20) domains of this meta-analysis.

Main effects of SQ-LNS on anemia and micronutrient status

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

Children who received SQ-LNS had significantly higher hemoglobin concentrations (2.77 g/L) relative to the control, and SQ-LNS reduced the prevalence of anemia and moderate to severe anemia by 16% (10 percentage points) and 28% (7 percentage points), respectively. Although these effects are smaller than what was reported in the 2019 Cochrane systematic review and meta-analysis of LNS (SQ- or MQ-LNS) for hemoglobin (MD: 5.74 (2.27, 9.30) g/L) and anemia (RR: 0.79 (0.69, 0.90)) (7), our meta-analysis includes a larger number of trials and individual participants (N = 13 trials and 15,562 participants) as compared to the Das et al. metaanalysis (N = 4-5 trials and 2,332-4,518 participants), which increases the precision of the effect estimates. Furthermore, we report estimates for iron deficiency and IDA, which were not included in the previous meta-analysis of SQ- and MQ-LNS. SQ-LNS reduced the prevalence of iron deficiency (plasma ferritin $< 12 \mu g/L$) by 56% (22 percentage points) and the prevalence of IDA by 64% (14 percentage points). At endline, the prevalence of IDA across all studies among children in the control groups was 23.5%, compared with 7.9% among children who received SQ-LNS. These large relative and absolute reductions in the prevalence of iron deficiency and IDA due to SQ-LNS are important given that iron deficiency is the most common documented micronutrient deficiency globally (4) and IDA is associated with compromised mental, motor, socio-emotional and neural development (51).

The findings of the present SQ-LNS meta-analysis are similar to those reported in a recent Cochrane systematic review and meta-analysis of the effect of multiple micronutrient powders (MNP) on hemoglobin (MD: 2.74 (1.95, 3.53) g/L) and anemia (RR: 0.82 (0.76, 0.90))

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

(N = 16-20 trials and 9.927-10.509 participants) (52). Suchdev et al. also reported a 53% reduction in the prevalence of iron deficiency (as defined by trialists) by MNP (N = 7 trials and 1,634 participants); the effect of MNP on the prevalence of IDA was not reported. Another metaanalysis of MNP efficacy trials by Tam et al. reported relative reductions in the prevalence of iron deficiency and IDA of 50% and 55%, respectively (8). Of note, in most of the MNP trials, the dose of elemental iron was 10-12.5 mg/d (primarily as ferrous fumarate), whereas the SQ-LNS trials in our analyses provided only 6-9 mg/d (primarily as ferrous sulfate). In the present analyses, there was considerable heterogeneity in the effect of SQ-LNS on anemia (reductions ranging from 3 to 29 percentage points), iron deficiency (reductions ranging from 14 to 35 percentage points), and IDA (reductions ranging from 8 to 29 percentage points). This heterogeneity may be due to differences in population characteristics (e.g., baseline prevalence of anemia, iron deficiency and IDA, proportion of anemia attributable to nutritional deficiencies vs. underlying burdens of infection and other causes) and study-design characteristics. The more modest relative reduction in the prevalence of anemia than in IDA may reflect the influence of non-nutritional causes of anemia in these populations (e.g., genetic hemoglobin disorders and infection and inflammation including malaria, intestinal parasites and schistosomiasis). In addition, although SQ-LNS substantially reduced the prevalence of IDA, it did not completely eliminate IDA, possibly reflecting factors such as poor iron absorption (due to anti-nutritional compounds, gastric pH or intestinal or systemic inflammation) (1) or a hemoglobin cutoff for anemia that is set inappropriately high for infants and young children, especially in African populations (53-55). However, it is noteworthy that the endline prevalence

of iron deficiency among children who received SQ-LNS was approximately 16% (vs. 40%

among children in the control groups), which is comparable to the prevalence of iron deficiency among children 12-36 months of age in the United States of America (13.5%) (56).

We observed significant increases in RBP concentrations among children who received SQ-LNS, although the relative increase was small (7%). The difference in plasma retinol was in the same direction, but not statistically significant. Our ability to draw conclusions was limited due to small sample sizes (n = 663-1236). However, in populations with adequate vitamin A stores, serum retinol may not respond to an intervention due to homeostatic regulation (57). At endline, the prevalence of vitamin A deficiency (retinol or RBP < 0.70 µmol/L) in the control groups was low, ranging from 1.1 to 16.2%. In the majority of studies in this analysis that assessed vitamin A status (7 of 9), more than half of study participants had received high-dose vitamin A supplementation (100,000 – 200,000 IU) within the 6 months prior to outcome assessment. Therefore, in some study contexts, the daily low-dose of vitamin A provided in SO-LNS may not have provided an additive benefit. However, SQ-LNS did reduce the prevalence of vitamin A deficiency (RBP < 0.70 µmol/L) by 56% (corresponding to a modest 3 percentage point reduction, due to the low overall prevalence of deficiency) indicating the potential of this intervention to improve the status of those at-risk. There was no overall effect of the intervention on plasma zinc concentrations, consistent with results from zinc-fortified food and MNP trials (52, 58), potentially due to the low bioavailability of zinc in SQ-LNS when provided as part of a phytate-rich food matrix (59), or differences in post-absorptive metabolism between zinc supplements and zinc-fortified foods (60).

Effect modification

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

For both study- and individual-level effect modifiers, it is important to distinguish between the potential to *benefit* and the potential to *respond* (18). The potential to benefit is more likely when a population or an individual child is more vulnerable, e.g. due to a high prevalence of anemia or micronutrient deficiencies in the study population at baseline. However, in some cases, children who are more vulnerable may actually be *less* likely to respond to a nutritional intervention because of other constraints on nutritional status such as infection and inflammation or inadequate care. Thus, we will attempt to frame the following discussion of effect modifiers in this context.

Effect modification by study-level characteristics

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

Studies included in this analysis were conducted in a variety of geographic and environmental contexts (e.g., different regions, burdens of anemia and infection including malaria, community-level access to improved water, sanitation and hygiene, etc.) and used varying intervention designs (e.g. durations of supplementation, iron dose, frequency of contact between participants and study staff) and this enables us to examine whether these study context and design features modify the effects of SQ-LNS. However, it is difficult to disentangle the impact attributable to one effect modifier from the influence of other characteristics of the study and thus these results should be interpreted with caution. For example, studies that provided a higher iron dose were more likely to provide SQ-LNS supplements for a longer duration, be conducted in South Asia, and have a higher average compliance with supplementation (>80 %), thus making it difficult to disentangle the impact attributable to each specific study-level characteristic. In addition, it is important to note that due to concerns about adverse effects of iron supplementation in malaria endemic areas (61, 62), a number of the SQ-LNS studies in these analyses were purposefully designed to provide a lower iron dose in countries with a high burden of malaria (6).

The effect of SQ-LNS on hemoglobin concentrations was greater in studies with a higher burden of anemia (>60%), suggesting a greater potential to benefit from SQ-LNS in such populations. Similarly, the effect of MNP on hemoglobin concentrations has been shown to be greater in populations that were anemic at baseline vs. populations with mixed/unknown baseline anemia status (MD: 4.53 g/L vs. 3.05 g/L) (52). However, even in populations with a lower burden of anemia, both SQ-LNS and MNP significantly increased hemoglobin concentrations and reduced the prevalence of anemia. In the present analyses, increases in hemoglobin concentrations due to SQ-LNS were not significantly different between populations with and without a high burden of malaria (4.29 g/L vs. 2.59 g/L) or inflammation (3.84 g/L vs. 3.21 g/L). Thus, these results, coupled with the observation that statistically significant effects of SQ-LNS were found in both subgroups, do not support the hypothesis that populations with a high burden of malaria and inflammation have less of a potential to respond to iron interventions due to increased hepcidin concentrations and down-regulation of iron absorption (63, 64).

Effect modification by study-level water quality and sanitation did not reach statistical significance for the majority of hematological and iron status outcomes, with the exception of a greater percentage point reduction in iron deficiency due to SQ-LNS in study sites with a lower proportion of households with access to improved water quality and sanitation. This is likely due to a higher prevalence of iron deficiency among children in the study sites with less access to improved water quality and sanitation; among control group children, prevalence of iron deficiency was 57% in those study sites, compared to 28% in sites with greater access.

Greater reductions in the prevalence of anemia and iron deficiency were observed in trials that provided SQ-LNS for longer than 12 months, compared to a shorter duration (6-12 months). In addition, studies that reported higher average compliance (>80 %) showed greater

increases in hemoglobin concentrations and reductions in the prevalence of anemia, but we did not observe significant effect modification by frequency of contact with programmatic or study staff. Finally, we observed greater effects of SQ-LNS on the prevalence of anemia and increase in ferritin concentrations among studies that provided 9 mg/d vs. < 9 mg/d iron. Although it may be difficult to disentangle the impact attributable to each of these aforementioned study-level characteristics, they all suggest a greater effect among studies in which children received a higher total iron dose, either through a longer duration of supplementation, by higher compliance, or a higher daily iron dose. Consistent with this, meta-analyses of the effectiveness of MNP and iron supplements in infants and young children have also shown higher iron doses to have a greater impact on iron and hematological status (8, 52).

Effect modification by individual-level characteristics

The effects of SQ-LNS on hemoglobin concentrations and the prevalence of anemia were greater among children of older mothers compared to those of younger mothers (relative reductions in anemia of 17% vs. 13%, respectively). Similarly, SQ-LNS had a larger effect on both hemoglobin and ferritin concentrations among later-born, as compared with first-born children, and reduced the prevalence of anemia in these sub-groups by 12 vs. 7 percentage points, respectively. SQ-LNS also had a larger effect on stunting, underweight and MUAC among later-born vs. first-born children (19). These results likely indicate a greater potential to benefit among later-born children. For example, hemoglobin concentrations among control group children in this IPD analysis were lower among later-born than first-born children (105.5 g/L vs. 108.4 g/L). Later-born children, who have one or more older siblings, may compete more for caregiving and family resources than first-born children, making them more vulnerable to anemia and iron deficiency and therefore more likely to benefit from nutritional supplementation

targeted specifically to young children. In addition, later-born children, who are more likely to be born to older mothers, may be more vulnerable to micronutrient deficiencies due to poor maternal physiological status owing to high fertility rates and short inter-pregnancy intervals (65, 66).

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

The effects of SQ-LNS on biomarkers of hematological and iron status (i.e., ferritin, sTfR, ZPP) did not differ by child sex, with the exception of greater reductions in ZPP concentrations due to SQ-LNS among males vs. females (24% vs. 18%). The former may have had a greater potential to benefit, given that median ZPP concentrations were higher among control group males than females in this analysis (62.0 µmol/mol heme vs. 53.1 µmol/mol heme), and males tend to be more vulnerable to iron deficiency in infancy (67). However, both sexes responded positively to the intervention, with a 10 percentage point reduction in the prevalence of anemia and a 20-23 percentage point reduction in the prevalence of iron deficiency. Children who were anemic at baseline had greater increases in hemoglobin concentrations due to SQ-LNS than children who were not anemic at baseline, indicating a greater potential to benefit. A recent MNP trial also showed greater increases in hemoglobin concentrations due to MNP among children who were anemic vs. non-anemic at baseline (68). In addition, these results are consistent with our study-level effect modification results, which indicated that increases in hemoglobin due to SQ-LNS were greater in populations with a high vs. moderate burden of anemia. Increases in ferritin concentrations due to SQ-LNS were larger among children who were acutely malnourished at baseline, compared to those who were not. Among children in the control groups, median ferritin concentrations were lower among children with vs. without acute malnutrition (15.5 μ g/L vs. 19.5 μ g/L), also suggestive of a greater potential to benefit.

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

Although differences in the ability of populations to benefit or respond to SO-LNS by the study-level burden of malaria or inflammation appeared to be explained by the cut-off effect, we did observe some differences at the individual level. SQ-LNS reduced the prevalence of anemia by 34% (a 12 percentage point difference) among children without concurrent inflammation vs. 15% (a 5 percentage point difference) among children with elevated CRP and/or AGP concentrations, indicating a greater potential to respond among those without inflammation. As inflammation is itself a cause of anemia (i.e., anemia of chronic disease) and can inhibit absorption of iron (63), it is likely that a higher proportion of anemia in the subgroup of noninflamed children was amenable to nutritional supplementation. Among children with inflammation, non-nutritional causes of anemia may have been more prevalent (e.g., anemia attributable to acute or chronic infection and inflammation) (29, 69). In the present analyses, the proportion of anemia not due to iron deficiency was greater (54% vs. 35%) among children with inflammation vs. those without. In addition, it is possible that children without inflammation had a greater fractional absorption of iron relative to those with inflammation (70). Hepcidin, an important regulator of systemic iron balance, is elevated by inflammation thereby inhibiting iron absorption (63). While a few trials measured hepcidin, we had insufficient data to examine it in this analysis. However, greater increases in ferritin concentrations due to SQ-LNS were observed among children without inflammation (65% vs. 48%), although there were no differences in the effect of SQ-LNS on iron deficiency by inflammation status. Greater effects of SQ-LNS on reductions in the prevalence of anemia, and reductions in

sTfR concentrations, were seen among children in households with improved (vs. unimproved) water quality. Poor quality water or sanitation may increase the risk of anemia due to infection with soil transmitted helminths or environmental enteric dysfunction, which may increase

inflammation or reduce nutrient absorption. Among children in the control group, the prevalence of anemia was higher among children without (vs. with) access to improved water quality (69% vs. 56%). Thus, this effect modification might be seen as consistent with the inflammation effect modification results described above. Children with less exposure to gastrointestinal pathogens through contaminated water supplies may have less inflammation and thus may be more able to respond to the SQ-LNS intervention. However, these findings are in contrast with the observed greater effects of SQ-LNS on anemia and moderate-to-severe anemia among children in households with unimproved (vs. improved) sanitation. This may indicate a greater potential to benefit, given that the prevalences of anemia and moderate-to-severe anemia were higher among control group children in households with unimproved sanitation (by 7 and 10 percentage points, respectively). The contradictory effect modification results for water quality and sanitation are difficult to explain. It is notable, though, that water quality and sanitation did not modify the effect of SQ-LNS on hemoglobin concentrations, and there was evidence of beneficial effects of SQ-LNS in all subgroups of children.

Greater effects of SQ-LNS on ferritin concentrations and the prevalence of iron deficiency were seen among children for whom biomarkers were assessed in the rainy season. Among children in the control groups in this analysis, median ferritin concentrations were lower (13.9 µg/L vs. 16.1 µg/L), and the prevalence of iron deficiency higher (by 6 percentage points) when outcome assessments occurred during the rainy (vs. dry) season. Thus, it is possible that this represents a greater potential to benefit, whereby the supplemental iron provided by SQ-LNS compensates for seasonal differences in dietary intake and/or constraints on iron absorption (e.g., infection and inflammation). However, iron status at a given point in time reflects the cumulative effect of intake, absorption and utilization over many months, so it is unclear whether effect

modification by season is due to short-term, acute phenomena or longer-term exposure to adverse conditions that is correlated with season at outcome assessment. Other household-level characteristics, including SES and food security, did not generally modify the effect of SQ-LNS on anemia or iron biomarker outcomes.

With regard to individual-level effect modification of outcomes related to zinc and vitamin A status, observed differences between the stratum-specific point estimates were generally small even when there were statistically significant p-values. In the latter situation, results were generally consistent with effect modification for hematological and iron status biomarkers, whereby children of older mothers, children who were acutely malnourished at baseline, children in households of higher SES and with greater food security, and children assessed during the rainy season had greater increases in biomarker concentrations or reductions in the prevalence of deficiency vs. those in the respective comparison sub-groups.

Strengths and limitations

Strengths of the present analyses include the large sample size, the substantial number of high-quality RCTs available, and the availability of individual participant data for all but one of the eligible trials. In addition, we were able to report the effects of SQ-LNS on multiple indicators of micronutrient status that had not been included in prior meta-analyses. The majority of trials used the same analytical laboratory and platform for several biomarkers (ferritin, sTfR, RBP; Vit-Min Lab) or standardized analytical methods (ZPP), lending strength to the findings. The trial sites were diverse in terms of study context (e.g., burdens of anemia, malaria and inflammation) and design (e.g., iron dose and duration of supplementation), which provided heterogeneity for exploration of study-level effect modifiers. The findings were generally

consistent across sensitivity analyses, as well as between fixed- and random-effects models, adding strength to the conclusions.

Several limitations must be considered. Bangladesh was the only country represented in these analyses outside of sub-Saharan Africa. Although hemoglobin data were available for all thirteen trials, fewer studies assessed biomarkers of iron, zinc and vitamin A status (3-7 studies) and sample sizes for each of those biomarkers were smaller (1,133 – 3,078 vs. 15,398 for hemoglobin). In addition, data were not yet available from a sufficient number of studies to be able to investigate the effects of SQ-LNS on additional biomarkers, including plasma hepcidin, folate, and vitamin B12 concentrations. Furthermore, not all trials assessed both CRP and AGP in all children at endline, potentially limiting the accuracy of adjustments for inflammation and/or reducing the available sample size. It should also be noted that a single assessment of inflammation may not adequately characterize the inflammation status of individual children over time, and the effects that average inflammation status over the entire period of supplementation may have on micronutrient status.

Due to limitations in the data (e.g., number of studies that assessed biomarker outcomes or effect modifiers of interest, or a low prevalence of the binary outcome or proportion of children within one of the effect modifier subgroups), we were unable to generate effect estimates of SQ-LNS on all biomarkers by all potential effect modifiers for all trials. Overall, statistical power for study-level effect modification was constrained by the limited number of trials, so there may be meaningful differences in effect estimates between categories of trials even if the p-diff for interaction was not significant. On the other hand, the individual-level effect modification analyses involved multiple effect modifiers and numerous outcomes, so several of the significant p-for-interaction values are likely due to chance. As stated in the

Methods section, we did not adjust for multiple hypothesis testing because the effect modification analyses are inherently exploratory. Finally, effect modification results should be interpreted with caution, as potential effect modifiers may be inter-related or confounded by unmeasured variables. This is particularly important for study-level characteristics because, as previously noted, it was not possible to completely disentangle the impact attributable to a specific effect modifier from the impact attributable to other characteristics of the study (e.g., study design, context, implementation, etc.).

Programmatic Implications

The present findings suggest that policy-makers and program planners should consider SQ-LNS in the mix of interventions to prevent anemia and iron and vitamin A deficiencies. The overall effects of SQ-LNS on iron deficiency (56% reduction) and IDA (64% reduction) were substantial and may improve child neurological development and immune function (71). Although the overall effects on anemia and moderate-to-severe anemia were more modest (16% and 28% reductions, respectively), this likely reflects the presence of anemias in these populations that are not nutrition responsive (e.g., genetic hemoglobin disorders and infection and inflammation). Alternative interventions, including micronutrient supplementation, MNP and food fortification are also effective in reducing anemia and the prevalence of iron deficiency (8, 52); however, SQ-LNS provides the added benefits of reducing mortality (72), stunting and wasting (19) and improving developmental outcomes (20).

In terms of program design, the effect modification results herein suggest that a greater impact of SQ-LNS on hematological and iron status outcomes may be obtained by providing formulations with the higher dose of iron (9 mg/d) and/or providing SQ-LNS for the entire window from 6-24 months. The iron dose of fortified products has been of concern because of

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

evidence that iron-containing supplements and MNP may increase susceptibility to malaria in endemic regions, as well as respiratory and gastrointestinal infections (61, 73-75), although two recent systematic reviews and meta-analyses did not indicate any increase in the risk of diarrhea or malaria from these interventions (52, 76). The present analysis did not examine potential adverse impacts (e.g., morbidity or mortality) of SQ-LNS by iron dose, malaria burden or other potential effect modifiers. However, most published trials have not reported differences in diarrheal or malarial morbidity between SQ-LNS and control groups (40, 42-44, 47, 48, 77-79), and some reported beneficial effects of SQ-LNS on diarrheal prevalence (37) and duration of pneumonia, diarrhea and dysentery (35). In addition, a recent meta-analysis reported an overall 27% reduction in the risk of mortality among children who received SQ-LNS vs. control (72). The majority of studies providing the higher iron dose were in lower malaria burden sites (36, 37, 42), and as such, we cannot recommend universal use of higher iron dose SO-LNS supplements at this time. In areas with a low prevalence of malaria and inflammation, or in malaria endemic areas with a well-integrated control program with appropriate surveillance and the prevention and management of malaria, providing the higher iron dose (9 mg/d) in SQ-LNS may be appropriate and have a greater impact on iron status and hematological parameters. Provision of SQ-LNS containing 9 mg/d iron for 18 months would cumulatively provide approximately 4,925 mg of iron, compared with the 2,200 mg of iron provided by 12 months of SQ-LNS containing 6 mg/d iron, but would increase programmatic costs. The effect modification results for biochemical outcomes generally did not provide a

The effect modification results for biochemical outcomes generally did not provide a strong rationale for *targeting* SQ-LNS only to the most vulnerable children or populations. Even in situations that were indicative of a greater potential to benefit among one sub-group compared to another (e.g., greater increases in hemoglobin concentrations among later-born vs. first-born

children and among anemic vs. non-anemic children, greater increases in ferritin concentrations among acutely malnourished vs. non-malnourished children), both sub-groups responded positively and appeared to benefit from the intervention. However, some of the results suggested that a greater impact of SQ-LNS may be obtained by *combining* supplementation with interventions that address factors related to the potential to respond. Integrating the provision of SQ-LNS with interventions to address the prevention and control of infection and inflammation (e.g., household and/or community level improvements in water, sanitation and hygiene, use of insecticide treated bed nets, and surveillance and treatment of diarrhea and malaria) may increase nutrient (iron) absorption, and thus increase the efficacy of the supplement.

There is now substantial evidence demonstrating the efficacy of SQ-LNS for prevention of anemia and iron deficiency. However, further research is needed to investigate the efficacy of SQ-LNS for prevention of other vitamin and mineral deficiencies. In the present analysis, there was insufficient evidence to assess the effect of SQ-LNS on folate and vitamin B12 status, and no trials assessed status regarding other B-vitamins, vitamin C, vitamin D and vitamin E, or minerals other than iron and zinc. Additional research is also needed on the optimal iron dose in SQ-LNS and the duration of supplementation, with regard to not only iron status and anemia but also morbidity, the costs and benefits of shorter vs. longer supplementation, and the potential to align the intervention with periods of increased vulnerability. Finally, further research would be useful to determine the optimal doses and formulations of micronutrients to include in SQ-LNS, and to investigate the effect of additional compounds, such as phytase or galactooligosaccharides, that may improve mineral bioavailability.

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

We thank all of the co-investigators, collaborators, study teams, participants and local communities involved in the trials included in these analyses. These trials benefitted from the contributions of many partner organizations, including: icddr,b (JiVitA-4, Rang-Din Nutrition Study and WASH Benefits trial in Bangladesh); the World Food Program (JiVitA-4 trial in Bangladesh); the Health District of Dandé and the relevant local health-care authorities (iLiNS-ZINC trial in Burkina Faso); AfricSanté and Helen Keller International (PROMIS trials in Burkina Faso and Mali); Innovations for Poverty Action and the Kenya Medical Research Institute (WASH-Benefits trial in Kenya); Unité Programme National de Nutrition Communautaire, Government of Madagascar, Institute Pasteur, and World Bank Health and Nutrition and Population Global Practice (MAHAY trial in Madagascar); the Ministry of Health and Child Care in Harare, Chirumanzu and Shurugwi districts, and Midlands Province (SHINE trial in Zimbabwe); the International Lipid-based Nutrient Supplements Project Steering Committee (iLiNS Project trials); and Nutriset (for development of SQ-LNS). We thank Emily Smith for advice on IPD analysis methods. The authors' responsibilities were as follows—KRW: drafted the manuscript with input from KGD, CDA, ELP, CPS and other coauthors; KRW, CDA, KGD, ELP and CPS: wrote the statistical analysis plan; BFA, PA, EB, LH: reviewed, contributed to, and approved the statistical analysis plan; KRW and CDA: compiled the data; CDA: conducted the data analysis; and all authors: read, contributed to, and approved the final manuscript.

Supported by Bill & Melinda Gates Foundation grant OPP49817 (to KGD). BA received travel support (airfare and hotel) covered by the Bill & Melinda Gates Foundation to attend meetings in Seattle during the period of this IPD analysis project; PC was an employee of the Bill & Melinda Gates Foundation when this project was conceived until December 2019. All other authors report no conflicts of interest.

- 1. Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, Ezzati M, Grantham-McGregor S, Katz J, Martorell R, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. Lancet 2013;382:427-51.
- 2. Muthayya S, Rah JH, Sugimoto JD, Roos FF, Kraemer K, Black RE. The global hidden hunger indices and maps: an advocacy tool for action. PLoS One 2013;8:e67860.
- 3. Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, Regan M, Weatherall D, Chou DP, Eisele TP, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood 2014;123:615-24.
- 4. Bailey RL, West KP, Jr., Black RE. The epidemiology of global micronutrient deficiencies. Ann Nutr Metab 2015;66 Suppl 2:22-33.
- 5. United Nations Children's Fund (UNICEF). Improving Child Nutrition: The Achievable Imperative for Global Progress. New York, UNICEF, 2013. Available at: https://www.unicef.org/publications/index_68661.html. Accessed on: 25 September 2020.
- 6. Arimond M, Zeilani M, Jungjohann S, Brown KH, Ashorn P, Allen LH, Dewey KG. Considerations in developing lipid-based nutrient supplements for prevention of undernutrition: experience from the International Lipid-Based Nutrient Supplements (iLiNS) Project. Matern Child Nutr 2015;11 Suppl 4:31-61.
- 7. Das JK, Salam RA, Hadi YB, Sadiq Sheikh S, Bhutta AZ, Weise Prinzo Z, Bhutta ZA. Preventive lipid-based nutrient supplements given with complementary foods to infants and young children 6 to 23 months of age for health, nutrition, and developmental outcomes. Cochrane Database Syst Rev 2019;5:CD012611.
- 8. Tam E, Keats EC, Rind F, Das JK, Bhutta AZA. Micronutrient supplementation and fortification interventions on health and development outcomes among children underfive in low- and middle-income countries: a systematic review and meta-analysis. Nutrients 2020;12:289.
- 9. Adu-Afarwuah S, Lartey A, Brown KH, Zlotkin S, Briend A, Dewey KG. Home fortification of complementary foods with micronutrient supplements is well accepted and has positive effects on infant iron status in Ghana. Am J Clin Nutr 2008;87:929-38.
- 10. Matias SL, Mridha MK, Young RT, Khan MSA, Siddiqui Z, Ullah MB, Vosti SA, Dewey KG. Prenatal and postnatal supplementation with lipid-based nutrient supplements reduces anemia and iron deficiency in 18-month-old Bangladeshi children: a cluster-randomized effectiveness trial. J Nutr 2018;148:1167-76.
- 11. Abbeddou S, Jimenez E, Some J, Ouedraogo J, Brown KH, Hess S. Small-quantity lipid-based nutrient supplements containing different amounts of zinc along with diarrhea and malaria treatment increase iron and vitamin A status and reduce anemia prevalence, but do not affect zinc status in young Burkinabe children: a cluster-randomized trial. BMC Pediatrics 2017:17.
- 12. Stewart CP, Dewey KG, Lin A, Pickering AJ, Byrd KA, Jannat K, Ali S, Rao G, Dentz HN, Kiprotich M, et al. Effects of lipid-based nutrient supplements and infant and young child feeding counseling with or without improved water, sanitation, and hygiene (WASH) on anemia and micronutrient status: results from 2 cluster-randomized trials in Kenya and Bangladesh. Am J Clin Nutr 2019;109:148-64.

- 13. Stewart CP, Fernald LCH, Weber AM, Arnold C, Galasso E. Lipid-based nutrient supplementation reduces child anemia and increases micronutrient status in Madagascar: a multiarm cluster-randomized controlled trial. J Nutr 2020;150:958-66.
- 14. Smuts CM, Matsungo TM, Malan L, Kruger HS, Rothman M, Kvalsvig JD, Covic N, Joosten K, Osendarp SJM, Bruins MJ, et al. Effect of small-quantity lipid-based nutrient supplements on growth, psychomotor development, iron status, and morbidity among 6-to 12-mo-old infants in South Africa: a randomized controlled trial. Am J Clin Nutr 2019;109:55-68.
- 15. Campbell RK, Shaikh S, Schulze K, Arguello M, Ali H, Wu L, West KP, Jr., Christian P. Micronutrient and inflammation status following one year of complementary food supplementation in 18-month-old rural Bangladeshi children: a randomized controlled trial. Nutrients 2020;12.
- 16. Adu-Afarwuah S, Young RT, Lartey A, Okronipa H, Ashorn P, Ashorn U, Oaks BM, Arimond M, Dewey KG. Maternal and infant supplementation with small-quantity lipid-based nutrient supplements increases infants' iron status at 18 months of age in a semiurban setting in Ghana: a secondary outcome analysis of the iLiNS-DYAD randomized controlled trial. J Nutr 2019;149:149-58.
- 17. Dewey KG, Mridha MK, Matias SL, Cummins JR, Arnold CD, Young RT, Maalouf-Manasseh Z, Vosti SA. Effectiveness of home fortification with lipid-based nutrient supplements (LNS) or micronutrient powder on child growth, development, micronutrient status, and health expenditures in Bangladesh. Washington, DC: FHI 360/Food and Nutrition Technical Assistance III Project (FANTA). 2017.
- 18. Dewey KG. Reducing stunting by improving maternal, infant and young child nutrition in regions such as South Asia: evidence, challenges and opportunities. Matern Child Nutr 2016;12 Suppl 1:27-38.
- 19. Dewey KG, Wessells KR, Arnold CD, Prado EL, Abbeddou S, Adu-Afarwuah S, Ali H, Arnold BF, Ashorn P, Ashorn U, et al. Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child growth: an individual participant data meta-analysis of randomized controlled trials. Amer J Clin Nutr, in this supplement.
- 20. Prado EL, Arnold CD, Wessells KR, Stewart CP, Abbeddou S, Adu-Afarwuah S, Arnold BF, Ashorn U, Ashorn P, Becquey E, et al. Small-quantity lipid-based nutrient supplements for children age 6-24 months: a systematic review and individual participant data meta-analysis of effects on developmental outcomes and effect modifiers. Amer J Clin Nutr, in this supplement.
- 21. Wessells K, Dewey K, Stewart C, Arnold C, Prado E. Modifiers of the effect of LNS provided to infants and children 6 to 24 months of age on anemia and MN status outcomes: a systematic review and meta-analysis of individual participant data from randomized controlled trials in low-income and middle-income countries. PROSPERO 2020 CRD42020156663 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020156663.
- 22. Wessells KR, Stewart C, Arnold CD, Dewey K, Prado E. Modifiers of the effect of LNS provided to infants and children 6 to 24 months of age on growth, anemia, micronutrient status and development outcomes. Open Science Framework. Available from: https://osf.io/ymsfu.

- 23. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF, Group P-ID. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. JAMA 2015;313:1657-65.
- 24. World Bank Historical Classification by Income Group. Available at: http://databank.worldbank.org/data/download/site-content/OGHIST.xls Accessed on: 22 August 2019.
- 25. Johnston BC, Guyatt GH. Best (but oft-forgotten) practices: intention-to-treat, treatment adherence, and missing participant outcome data in the nutrition literature. Am J Clin Nutr 2016;104:1197-201.
- 26. Higgins J, Green S. Cochrane Handbook for Systematic Reviews for Interventions, Version 5.1.0. The Cochrane Collaboration 2011. Available from www.handbook.cochrane.org.
- 27. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6.
- 28. World Health Organization. Iron deficiency anaemia: assessment, prevention, and control. A guide for programme managers. Geneva, World Health Organization, 2001.
- 29. Namaste SM, Aaron GJ, Varadhan R, Peerson JM, Suchdev PS, Brinda Working Group. Methodologic approach for the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project. Am J Clin Nutr 2017;106:333S-47S.
- 30. Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med 2017;36:855-75.
- 31. Huber PJ. The behavior of maximum likelihood estimates under non-standard conditions. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability; University of California Press; Berkeley, CA. 1967. pp. 221–233.
- 32. Paule RC, Mandel J. Consensus values, regressions, and weighting factors. J Res Natl Inst Stand Technol 1989;94:197-203.
- 33. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ 2003;327:557-60.
- 34. Streiner DL. Best (but oft-forgotten) practices: the multiple problems of multiplicity-whether and how to correct for many statistical tests. Am J Clin Nutr 2015;102:721-8.
- 35. Christian P, Shaikh S, Shamim AA, Mehra S, Wu L, Mitra M, Ali H, Merrill RD, Choudhury N, Parveen M, et al. Effect of fortified complementary food supplementation on child growth in rural Bangladesh: a cluster-randomized trial. Int J Epidemiol 2015;44:1862-76.
- 36. Dewey KG, Mridha MK, Matias SL, Arnold CD, Cummins JR, Khan MS, Maalouf-Manasseh Z, Siddiqui Z, Ullah MB, Vosti SA. Lipid-based nutrient supplementation in the first 1000 d improves child growth in Bangladesh: a cluster-randomized effectiveness trial. Am J Clin Nutr 2017;105:944-57.
- 37. Luby SP, Rahman M, Arnold BF, Unicomb L, Ashraf S, Winch PJ, Stewart CP, Begum F, Hussain F, Benjamin-Chung J, et al. Effects of water quality, sanitation, handwashing, and nutritional interventions on diarrhoea and child growth in rural Bangladesh: a cluster randomised controlled trial. Lancet Glob Health 2018;6:e302-e15.
- 38. Hess SY, Abbeddou S, Jimenez EY, Some JW, Vosti SA, Ouedraogo ZP, Guissou RM, Ouedraogo JB, Brown KH. Small-quantity lipid-based nutrient supplements, regardless

- of their zinc content, increase growth and reduce the prevalence of stunting and wasting in young Burkinabe children: a cluster-randomized trial. PLoS One 2015;10:e0122242.
- 39. Becquey E, Huybregts L, Zongrone A, Le Port A, Leroy JL, Rawat R, Toure M, Ruel MT. Impact on child acute malnutrition of integrating a preventive nutrition package into facility-based screening for acute malnutrition during well-baby consultation: a cluster-randomized controlled trial in Burkina Faso. PLoS Med 2019;16:e1002877.
- 40. Adu-Afarwuah S, Lartey A, Brown KH, Zlotkin S, Briend A, Dewey KG. Randomized comparison of 3 types of micronutrient supplements for home fortification of complementary foods in Ghana: effects on growth and motor development. Am J Clin Nutr 2007;86:412-20.
- 41. Adu-Afarwuah S, Lartey A, Okronipa H, Ashorn P, Peerson JM, Arimond M, Ashorn U, Zeilani M, Vosti S, Dewey KG. Small-quantity, lipid-based nutrient supplements provided to women during pregnancy and 6 mo postpartum and to their infants from 6 mo of age increase the mean attained length of 18-mo-old children in semi-urban Ghana: a randomized controlled trial. Am J Clin Nutr 2016;104:797-808.
- 42. Null C, Stewart CP, Pickering AJ, Dentz HN, Arnold BF, Arnold CD, Benjamin-Chung J, Clasen T, Dewey KG, Fernald LCH, et al. Effects of water quality, sanitation, handwashing, and nutritional interventions on diarrhoea and child growth in rural Kenya: a cluster-randomised controlled trial. Lancet Glob Health 2018;6:e316-e29.
- 43. Galasso E, Weber AM, Stewart CP, Ratsifandrihamanana L, Fernald LCH. Effects of nutritional supplementation and home visiting on growth and development in young children in Madagascar: a cluster-randomised controlled trial. Lancet Glob Health 2019;7:e1257-e68.
- 44. Ashorn P, Alho L, Ashorn U, Cheung YB, Dewey KG, Gondwe A, Harjunmaa U, Lartey A, Phiri N, Phiri TE, et al. Supplementation of maternal diets during pregnancy and for 6 months postpartum and infant diets thereafter with small-quantity lipid-based nutrient supplements does not promote child growth by 18 months of age in rural Malawi: a randomized controlled trial. J Nutr 2015;145:1345-53.
- 45. Maleta KM, Phuka J, Alho L, Cheung YB, Dewey KG, Ashorn U, Phiri N, Phiri TE, Vosti SA, Zeilani M, et al. Provision of 10-40 g/d lipid-based nutrient supplements from 6 to 18 months of age does not prevent linear growth faltering in Malawi. J Nutr 2015;145:1909-15.
- 46. Huybregts L, Le Port A, Becquey E, Zongrone A, Barba FM, Rawat R, Leroy JL, Ruel MT. Impact on child acute malnutrition of integrating small-quantity lipid-based nutrient supplements into community-level screening for acute malnutrition: a cluster-randomized controlled trial in Mali. PLoS Med 2019;16:e1002892.
- 47. Humphrey JH, Mbuya MNN, Ntozini R, Moulton LH, Stoltzfus RJ, Tavengwa NV, Mutasa K, Majo F, Mutasa B, Mangwadu G, et al. Independent and combined effects of improved water, sanitation, and hygiene, and improved complementary feeding, on child stunting and anaemia in rural Zimbabwe: a cluster-randomised trial. Lancet Glob Health 2019;7:e132-e47.
- 48. Prendergast AJ, Chasekwa B, Evans C, Mutasa K, Mbuya MNN, Stoltzfus RJ, Smith LE, Majo FD, Tavengwa NV, Mutasa B, et al. Independent and combined effects of improved water, sanitation, and hygiene, and improved complementary feeding, on stunting and anaemia among HIV-exposed children in rural Zimbabwe: a cluster-randomised controlled trial. Lancet Child Adolesc Health 2019;3:77-90.

- 49. Iannotti LL, Dulience SJ, Green J, Joseph S, Francois J, Antenor ML, Lesorogol C, Mounce J, Nickerson NM. Linear growth increased in young children in an urban slum of Haiti: a randomized controlled trial of a lipid-based nutrient supplement. Am J Clin Nutr 2014;99:198-208.
- 50. World Malaria Report 2018. Geneva: World Health Organization; 2018. Available at: https://www.who.int/malaria/publications/world-malaria-report-2018/report/en/ Accessed on: 26 August 2019.
- 51. Walker SP, Wachs TD, Gardner JM, Lozoff B, Wasserman GA, Pollitt E, Carter JA, International Child Development Steering G. Child development: risk factors for adverse outcomes in developing countries. Lancet 2007;369:145-57.
- 52. Suchdev PS, Jefferds MED, Ota E, da Silva Lopes K, De-Regil LM. Home fortification of foods with multiple micronutrient powders for health and nutrition in children under two years of age. Cochrane Database Syst Rev 2020;2:CD008959.
- 53. Domellof M, Dewey KG, Lonnerdal B, Cohen RJ, Hernell O. The diagnostic criteria for iron deficiency in infants should be reevaluated. J Nutr 2002;132:3680-6.
- 54. Nestel P and the INACG Sterring Committee. Adjusting hemoglobin values in program surveys. Available from: http://pdf.usaid.gov/pdf_docs/PNACQ927.pdf. Accessed on: 2 December 2020.
- 55. Jorgensen JM, Crespo-Bellido M, Dewey KG. Variation in hemoglobin across the life cycle and between males and females. Ann N Y Acad Sci 2019;1450:105-25.
- 56. Gupta PM, Perrine CG, Mei Z, Scanlon KS. Iron, anemia, and iron deficiency anemia among young children in the United States. Nutrients 2016;8.
- 57. Tanumihardjo SA, Russell RM, Stephensen CB, Gannon BM, Craft NE, Haskell MJ, Lietz G, Schulze K, Raiten DJ. Biomarkers of Nutrition for Development (BOND)-Vitamin A Review. J Nutr 2016;146:1816S-48S.
- 58. Hess SY, Brown KH. Impact of zinc fortification on zinc nutrition. Food Nutr Bull 2009;30:S79-107.
- 59. Zyba SJ, Wegmuller R, Woodhouse LR, Ceesay K, Prentice AM, Brown KH, Wessells KR. Effect of exogenous phytase added to small-quantity lipid-based nutrient supplements (SQ-LNS) on the fractional and total absorption of zinc from a millet-based porridge consumed with SQ-LNS in young Gambian children: a randomized controlled trial. Am J Clin Nutr 2019;110:1465-75.
- 60. King JC, Brown KH, Gibson RS, Krebs NF, Lowe NM, Siekmann JH, Raiten DJ. Biomarkers of Nutrition for Development (BOND) Zinc Review. J Nutr 2016;146:858S-85S.
- 61. Sazawal S, Black RE, Ramsan M, Chwaya HM, Stoltzfus RJ, Dutta A, Dhingra U, Kabole I, Deb S, Othman MK, et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. Lancet 2006;367:133-43.
- 62. Report of the World Health Organization Technical Consultation on Prevention and Control of Iron Deficiency in Infants and Young Children in Malaria-Endemic Areas, Lyon, France, 12-14 June 2006. Food Nutr Bull 2007;28:S489-631.
- 63. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009;122:78-86.

- 64. Muriuki JM, Atkinson SH. How eliminating malaria may also prevent iron deficiency in African children. Pharmaceuticals (Basel) 2018;11.
- 65. King JC. The risk of maternal nutritional depletion and poor outcomes increases in early or closely spaced pregnancies. J Nutr 2003;133:1732S-6S.
- 66. Winkvist A, Rasmussen KM, Habicht JP. A new definition of maternal depletion syndrome. Am J Public Health 1992;82:691-4.
- 67. Domellof M, Lonnerdal B, Dewey KG, Cohen RJ, Rivera LL, Hernell O. Sex differences in iron status during infancy. Pediatrics 2002;110:545-52.
- 68. Barffour MA, Hinnouho GM, Kounnavong S, Wessells KR, Ratsavong K, Bounheuang B, Chanhthavong B, Sitthideth D, Sengnam K, Arnold CD, et al. Effects of daily zinc, daily multiple micronutrient powder, or therapeutic zinc supplementation for diarrhea prevention on physical growth, anemia, and micronutrient status in rural Laotian children: a randomized controlled trial. J Pediatr 2019;207:80-9.
- 69. Balarajan Y, Ramakrishnan U, Ozaltin E, Shankar AH, Subramanian SV. Anaemia in low-income and middle-income countries. Lancet 2011;378:2123-35.
- 70. Hurrell RF. Influence of inflammatory disorders and infection on iron absorption and efficacy of iron-fortified foods. Nestle Nutr Inst Workshop Ser 2012;70:107-16.
- 71. Armitage AE, Moretti D. The importance of iron status for young children in low- and middle-income countries: a narrative review. Pharmaceuticals (Basel) 2019;12.
- 72. Stewart CP, Wessells KR, Arnold CD, Huybregts L, Ashorn P, Becquey E, Humphrey JH, Dewey KG. Lipid-based nutrient supplements and all-cause mortality in children 6-24 months of age: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2020;111:207-18.
- 73. Soofi S, Cousens S, Iqbal SP, Akhund T, Khan J, Ahmed I, Zaidi AK, Bhutta ZA. Effect of provision of daily zinc and iron with several micronutrients on growth and morbidity among young children in Pakistan: a cluster-randomised trial. Lancet 2013;382:29-40.
- 74. Veenemans J, Milligan P, Prentice AM, Schouten LR, Inja N, van der Heijden AC, de Boer LC, Jansen EJ, Koopmans AE, Enthoven WT, et al. Effect of supplementation with zinc and other micronutrients on malaria in Tanzanian children: a randomised trial. PLoS Med 2011;8:e1001125.
- 75. Paganini D, Uyoga MA, Zimmermann MB. Iron fortification of foods for infants and children in low-income countries: effects on the gut microbiome, gut inflammation, and diarrhea. Nutrients 2016;8.
- 76. Pasricha SR, Hayes E, Kalumba K, Biggs BA. Effect of daily iron supplementation on health in children aged 4-23 months: a systematic review and meta-analysis of randomised controlled trials. Lancet Glob Health 2013;1:e77-e86.
- 77. Ullah MB, Mridha MK, Arnold CD, Matias SL, Khan MSA, Siddiqui Z, Hossain M, Dewey KG. Provision of pre- and postnatal nutritional supplements generally did not increase or decrease common childhood illnesses in Bangladesh: a cluster-randomized effectiveness trial. J Nutr 2019;149:1271-81.
- 78. Adu-Afarwuah S, Young RR, Lartey A, Okronipa H, Ashorn P, Ashorn U, Oaks BM, Dewey KG. Supplementation with small-quantity lipid-based nutrient supplements does not increase child morbidity in a semiurban setting in Ghana: a secondary outcome noninferiority analysis of the International Lipid-Based Nutrient Supplements (iLiNS)-DYAD randomized controlled trial. J Nutr 2020;150:382-93.

- 79. Bendabenda J, Alho L, Ashorn U, Cheung YB, Dewey KG, Vosti SA, Phuka J, Maleta K, Ashorn P. The effect of providing lipid-based nutrient supplements on morbidity in rural Malawian infants and young children: a randomized controlled trial. Public Health Nutr 2016;19:1893-903.
- 80. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011 (WHO/NMH/NHD/MNM/11.1) Available at: http://www.who.int/vmnis/indicators/haemoglobin.pdf Accessed on: 18 January 2019.
- 81. World Health Organization. Serum ferritin concentrations for the assessment of iron status and iron deficiency in populations (WHO/NMH/NHD/MNM/11.2). Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011. Available at: https://www.who.int/vmnis/indicators/serum_ferritin.pdf. Accessed on: 18 January 2019.
- 82. Erhardt JG, Estes JE, Pfeiffer CM, Biesalski HK, Craft NE. Combined measurement of ferritin, soluble transferrin receptor, retinol binding protein, and C-reactive protein by an inexpensive, sensitive, and simple sandwich enzyme-linked immunosorbent assay technique. J Nutr 2004;134:3127-32.
- 83. Crowell R, Ferris AM, Wood RJ, Joyce P, Slivka H. Comparative effectiveness of zinc protoporphyrin and hemoglobin concentrations in identifying iron deficiency in a group of low-income, preschool-aged children: practical implications of recent illness. Pediatrics 2006;118:224-32.
- 84. Brown KH, Rivera JA, Bhutta Z, Gibson RS, King JC, Lönnerdal B, Ruel MT, Sandtröm B, Wasantwisut E, Hotz C. International Zinc Nutrition Consultative Group (IZiNCG) technical document #1. Assessment of the risk of zinc deficiency in populations and options for its control. Food Nutr Bull 2004;25:S99-203.
- 85. World Health Organization. Serum retinol concentrations for determining the prevalence of vitamin A deficiency in populations (WHO/NMH/NHD/MNM/11.3). Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011. Available at: https://www.who.int/vmnis/indicators/retinol.pdf. Accessed on: 18 January 2019.
- 86. de Pee S, Dary O. Biochemical indicators of vitamin A deficiency: serum retinol and serum retinol binding protein. J Nutr 2002;132:2895S-901S.
- 87. Pasricha SR, Atkinson SH, Armitage AE, Khandwala S, Veenemans J, Cox SE, Eddowes LA, Hayes T, Doherty CP, Demir AY, et al. Expression of the iron hormone hepcidin distinguishes different types of anemia in African children. Sci Transl Med 2014;6:235re3.
- 88. Bailey LB, Stover PJ, McNulty H, Fenech MF, Gregory JF, 3rd, Mills JL, Pfeiffer CM, Fazili Z, Zhang M, Ueland PM, et al. Biomarkers of Nutrition for Development-Folate Review. J Nutr 2015;145:1636S-80S.
- 89. Allen LH, Miller JW, de Groot L, Rosenberg IH, Smith AD, Refsum H, Raiten DJ. Biomarkers of Nutrition for Development (BOND): Vitamin B-12 Review. J Nutr 2018;148:1995S-2027S.
- 90. WHO, UNICEF Joint Monitoring Programme. Drinking Water. Available at http://washdata.org/monitoring/drinking-water. Accessed on: 26 August 2019.
- 91. WHO, UNICEF Joint Monitoring Programme. Sanitation. Available at http://washdata.org/monitoring/sanitation. Accessed on: 26 August 2019.

Outcome variables	Definitions of dichotomous outcome variables
Hemoglobin (Hb; g/L)	
Anemia	Hb < 110 g/L (80)
Moderate to severe anemia	Hb < 100 g/L (80)
Plasma ferritin (µg/L)	
Iron deficiency (low plasma ferritin	Plasma ferritin < 12 µg/L (81)
concentration)	
Iron deficiency anemia	Plasma ferritin $<12 \mu g/L Hb < 110 g/L (28)$
Plasma soluble transferrin receptor	
concentration (sTfR; mg/L)	
Elevated plasma sTfR concentration	Plasma sTfR > 8.3 mg/L (82)
Erythrocyte zinc protoporphyrin	
concentration (ZPP; µmol/mol heme)	
Elevated ZPP	Erythrocyte ZPP $> 70 \mu \text{mol/mol heme}$ (83)
Plasma zinc concentration (µg/dL)	
Low plasma zinc concentration	Plasma zinc $< 65 \mu g/dL (84)$
Plasma retinol concentration (µmol/L)	
Low retinol	Plasma retinol < 0.70 μmol/L (85)
Marginal retinol	Plasma retinol $< 1.05 \mu\text{mol/L}$ (85)
Plasma retinol binding protein	
concentration (RBP; µmol/L)	
Low RBP	Plasma RBP < 0.70 μmol/L (86)
Marginal RBP	Plasma RBP $< 1.05 \mu\text{mol/L}$ (86)

Hb, hemoglobin; RBP, retinol binding protein; sTfR, soluble transferrin receptor; ZPP, zinc protoporphyrin.

¹Plasma hepcidin concentration (ng/mL), low hepcidin (< 5.5 ng/mL) (87), plasma folate concentration (nmol/L), low folate (< 10 nmol/L) (88), plasma vitamin B12 concentration (pmol/L), low vitamin B12 (< 150 pmol/L), and depleted vitamin B12 (<221 pmol/L) (89) were also considered as outcome variables, however data were not yet available from a sufficient number of trials to be included in the present analyses.

Box 2. Potential effect modifiers

Study-level effect modifiers

- Geographic region (WHO region: African vs. South-East Asia Region)
- Anemia burden (country-specific, closest in time to the study: < 60% vs. > 60%)¹
- Malaria prevalence (country-specific, closest in time to the study: $< 10\% \text{ vs.} \ge 10\%$)²
- Inflammation prevalence (study-specific:, elevated CRP ≤ 25% and/or elevated AGP ≤ 50% vs. elevated CRP > 25% and/or elevated AGP > 50%)³
- Water quality (study-specific: < 75% vs. ≥ 75% prevalence of improved drinking water)⁴
- Sanitation (study specific: < 50% vs. ≥ 50% prevalence of improved sanitation)⁵
- Duration of child supplementation (study target: > 12 mo vs. ≤ 12 mo)
- Iron dose in the SQ-LNS product (9 mg/d vs. < 9 mg/d)⁶
- Child age at baseline or endline
- Frequency of contact for intervention delivery or outcome assessments during the study (weekly vs. monthly)
- Compliance (average percent compliance in LNS group \geq 80% vs. <80%)⁷

Individual-level effect modifiers

- Maternal BMI ($< 20 \text{ kg/m}^2 \text{ vs.} > 20 \text{ kg/m}^2$)
- Maternal age (< 25 y vs. > 25 y)
- Maternal education (no formal or incomplete primary vs. complete primary or greater)
- Child sex (female vs. male)
- Child birth order (first born vs. later born)
- Child baseline acute malnutrition (WLZ < -2 SD or MUAC < 125 mm vs. WLZ ≥ -2 SD and MUAC ≥ 125 mm; if MUAC not measured, WLZ < -2 SD vs. WLZ > -2 SD)
- Child baseline anemia status (Hb \geq 110 g/L vs. < 110 g/L); iron outcomes only
- Child high-dose vitamin A supplementation (receipt within six months prior to outcome assessment vs. non-receipt)
- Child inflammation at time of outcome assessment (CRP ≤ 5 mg/L and AGP ≤ 1 g/L vs. not)
- Household socio-economic status (< study median vs. > study median)⁸
- Food security (moderate to severe food insecurity vs. mild to secure)
- Water quality (unimproved vs. improved)⁵
- Sanitation (unimproved vs. improved)⁶
- Season at the time of outcome assessment (rainy vs. dry)⁹

¹ Country-specific prevalence of anemia among children 6-59 months, based on national surveys (see Supplemental Table 3)

² Country-specific prevalence of malaria, based on World Malaria Report 2018 (see Supplemental Table 3) (50)

 $^{^3}$ Elevated CRP defined as > 5 mg/L, elevated AGP defined as > 1 g/L.

⁴ study-specific prevalence (see Supplemental Table 3) (90)

⁵ study-specific prevalence (see Supplemental Table 3) (91)

⁶ study-specific (see Supplemental Tables 2 and 3)

⁷ study-specific, as reported based on a study-defined indicator (see Supplemental Table 3)

⁸ based on a study-defined, study-specific assets index

⁹ rainy vs. dry, based on study- and child-specific average rainfall during the month of measurement and two months prior (see Supplemental Methods and Supplemental Table 4)

medRxiv preprint doi: https://doi.org/10.1101/2021.02.08.21251234; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Table 1. Characteristics of trials included in the individual participant data analysis

Country, years of study, study Name, trial design, (author date) ¹		SQ-LNS lement	Maternal SQ-LNS Supplement	Participa	nts, data avail	able (n) ²		of deficiency, at endline (%)
	Age at start	Duration		Endline assessment	Hb sub- sample	MN sub- sample	Anemia (Hb < 110 g/L)	Iron deficiency (ferritin < 12 μg/L)
Bangladesh, 2012-2014, JiVitA-4, cluster RCT, longitudinal follow-up (Christian 2015, Campbell 2020)	6 mo	12 mo	N	4568	603	600	15.8 %	22.2 %
Bangladesh, 2011-2015, RDNS, cluster RCT; longitudinal follow-up (Dewey 2017, Matias 2018)	6 mo	18 mo	Y/N	2567	821	822	41.9 %	22.1 %
Bangladesh, 2012-2015, WASH-Benefits, cluster RCT, cross-sectional surveys (Luby 2018, Stewart 2019)	6 mo	18 mo	N	4824	420	390	16.1 %	35.4 %
Burkina Faso, 2010-2012, iLiNS-ZINC, cluster RCT, longitudinal follow-up (Hess 2015, Abbeddou 2017)	9 mo	9 mo	N	2647	2621	456	91.1 %	58.5 %
Burkina Faso, 2015-2017, PROMIS, cluster RCT, cross-sectional surveys (Becquey 2019)	6 mo	12 mo	N	1157	1155	0	70.1 %	
Ghana, 2004-2005, RCT, longitudinal follow-up (Adu-Afarwuah 2007, Adu- Afarwuah 2008)	6 mo	6 mo	N	194	194	167	58.3 %	56.1 %
Ghana, 2009-2014, iLiNS-DYAD-G, RCT; longitudinal follow-up (Adu-Afarwuah 2016, Adu- Afarwuah 2019)	6 mo	12 mo	Y	1113	989	304	44.9 %	
Kenya, 2012-2016, WASH-Benefits, cluster RCT, cross-sectional surveys (Null 2018, Stewart 2019)	6 mo	18 mo	N	6815	650	631	47.3 %	59.1 %
Madagascar, 2014-2016, MAHAY, cluster RCT, longitudinal follow-up (Galasso 2019, Stewart 2020)	6-11 mo	6-12 mo	Y/N	3438	1188	134	64.8 %	51.0 %
Malawi, 2011-2014, iLiNS-DYAD-M, RCT, longitudinal follow-up (Ashorn 2015)	6 mo	12 mo	Y	675	642	582	51.9 %	
Malawi, 2009-2012, iLiNS-DOSE, RCT, longitudinal follow-up (Maleta 2015 ³)	6 mo	12 mo	N	1018	326	268	72.0 %	
Mali, 2015-2017, PROMIS, cluster RCT, cross-sectional surveys (Huybregts 2019)	6 mo	18 mo	N	1927	1923	0	86.2 %	
Zimbabwe, 2013-2017,SHINE ⁴ , cluster RCT, longitudinal follow-up (Humphrey 2019; Prendergast 2019)	6 mo	12 mo	N	4347	3867	0	35.3 % ⁵	

Hb, hemoglobin; MN, micronutrient; SQ-LNS, small-quantity lipid-based nutrient supplements; RCT, randomized controlled trial.

¹The first (author date) refer to the main publication for each trial. The second refers to an additional publication specific to hematological and micronutrient status outcomes.

²Endline assessment (n) includes the number of children for whom any data were available for at least one outcome included in the IPD analyses (growth, development and/or biochemical). MN sub-sample includes the number of children for whom any data were available for at least one micronutrient status outcome, plus CRP and/or AGP such that values could be adjusted for inflammation.

³Trial is cited as Kumwenda 2014 in Das et al. (Cochrane Database of Systematic Reviews 2019)

⁴Trial was designed *a priori* to present results separately for HIV exposed and un-exposed children; thus considered as two comparisons in all analyses and the presentation of results.

⁵Data are for the HIV unexposed cohort only. The prevalence of anemia in the HIV exposed cohort was 36.8%.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.08.21251234; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Table 2. The effect of SQ-LNS on hemoglobin and micronutrient status

Outcomes	Number of participants (comparisons)	Mean difference: LNS - control (95% CI)	P value	Heterogeneity I ² (p-for- heterogeneity) ¹	Quality of the evidence (GRADE)
Hemoglobin (Hb), g/L ²	15398 (14)	2.77 (2.30, 3.25)	< 0.001	0.72 (<0.001)	High
Outcomes	Number of participants (comparisons)	Ratio of geometric means: LNS / control (95% CI)	P value	Heterogeneity I ² (p-for- heterogeneity) ¹	Quality of the evidence (GRADE)
Ferritin, µg/L ²	3078 (7)	1.56 (1.48, 1.64)	< 0.001	0.53 (0.072)	High
Soluble transferrin receptor (sTfR), mg/L ²	2480 (6)	0.83 (0.80, 0.85)	< 0.001	0.46 (0.098)	High
Zinc protoporphyrin (ZPP), µmol/mol heme ²	1542 (4)	0.80 (0.75, 0.85)	< 0.001	0.79 (0.001)	Moderate
Plasma zinc, μg/dL	1133 (3)	1.00 (0.97, 1.02)	0.734	0.00 (0.416)	Low
Retinol, µmol/L	1236 (4)	1.04 (1.00, 1.08)	0.057	0.08 (0.360)	Moderate
Retinol binding protein (RBP), µmol/L	2314 (5)	1.07 (1.04, 1.09)	< 0.001	0.68 (0.017)	Moderate
Outcomes	Number of participants (comparisons)	Prevalence ratio: LNS / control (95% CI)	P value	Heterogeneity I ² (p-for- heterogeneity) ¹	Quality of the evidence (GRADE)
Anemia $(Hb < 110 \text{ g/L})^2$	15398 (14)	0.84 (0.81, 0.87)	< 0.001	0.65 (<0.001)	High
Moderate to severe anemia $(Hb < 100 \text{ g/L})^2$	14375 (12)	0.72 (0.68, 0.76)	< 0.001	0.64 (0.001)	High
Iron deficiency (ferritin $< 12 \mu g/L$) ²	3078 (7)	0.44 (0.39, 0.50)	< 0.001	0.66 (0.009)	High
Iron deficiency anemia (Hb < 110 g/L, ferritin < 12 μ g/L) ²	2702 (6)	0.36 (0.30, 0.44)	< 0.001	0.71 (0.004)	High
Elevated sTfR $(> 8.3 \text{ mg/L})^2$	2480 (6)	0.64 (0.59, 0.70)	< 0.001	0.73 (<0.001)	High
Elevated ZPP (>70 μmol/mol heme) ²	1542 (4)	0.70 (0.61, 0.79)	< 0.001	0.00 (0.881)	Moderate
Zinc deficiency (plasma zinc < 65 μg/dL)	537 (2)	-	-	-	-
Low Vitamin A status (retinol < 0.70 μmol/L)	663 (3)	1.02 (0.62, 1.69)	0.938	0.01 (0.581)	Low
Marginal vitamin A status (retinol < 1.05 μmol/L)	1236 (4)	0.98 (0.85, 1.13)	0.829	0.35 (0.206)	Moderate
	1700 (2)	0.44 (0.27, 0.70)	0.001	0.00 (0.713)	Moderate
Low vitamin A status (RBP < 0.70 μmol/L)	1790 (3)	0.44 (0.27, 0.70)	0.001	0.00 (0.713)	Moderate

Hb, hemoglobin; RBP, retinol binding protein; sTfR, soluble transferrin receptor concentration; ZPP, zinc protoporphyrin

medRxiv preprint doi: https://doi.org/10.1101/2021.02.08.21251234; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

 1 I 2 describes the percentage of variability in effect estimates that may be due to heterogeneity rather than chance. Roughly, 0.3 to 0.6 may be considered moderate heterogeneity, < 0.6 may be considered high heterogeneity. P-value from chi-squared test for heterogeneity. P < 0.05 indicates statistically significant evidence of heterogeneity of intervention effects beyond chance.

²Pre-specified as primary outcomes in the statistical analysis plan.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.08.21251234; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Table 3. Overview of study-level effect modification

	Hb	Ane	mia	Modera severe a		Ferritin	lron de	eficiency		eficiency emia	sTfR		ated fR
Effect modifier	MD	PR	PD	PR	PD	GMR	PR	PD	PR	PD	GMR	PR	PD
SE-Asia (vs. Africa)		(C)						С					
Moderate (vs. high) anemia burden		С			(C)								
Low (vs. high) malaria prevalence		С											
Lower (vs. higher) inflammation prevalence		С		С									
Improved (vs. unimproved) water quality 1									С				
Improved (vs. unimproved) sanitation ¹									С				
Supplement duration of more than 12 mo (vs. ≤ 12 months)				С									
9 mg (vs. < 9 mg) of iron				(C)									
Weekly (vs. monthly) frequency of contact												С	
Higher (vs. lower) compliance													

MD=mean difference; GMR=geometric mean ratio; PR=prevalence ratio; PD=prevalence difference; sTfR = soluble transferrin receptor. Green indicates stronger effect in the indicated subgroup while blue indicates a stronger effect in the other subgroup. Dark color indicates p-for-interaction < 0.05; light color indicates 0.05 . The letter "C" indicates that the apparent effect modification is due to the cutoff effect; when "C" is in parentheses, it is partially explained by the cutoff effect.

¹ For iron status biomarkers (ferritin and sTfR), water quality and sanitation sub-groups captured the same trials, so these characteristics are considered as a single effect modifier at the study-level. Water quality and sanitation sub-groups captured different trials for hemoglobin and anemia outcomes.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.08.21251234; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Table 4. Overview of individual-level effect modification

	Hb	Ane	mia	to-s	erate- evere emia	Ferritin		on iency	defic	on iency mia	sTfR		ated fR	ZPP	Elevat	ted ZPP
Effect modifier	MD	PR	PD	PR	PD	GMR	PR	PD	PR	PD	GMR	PR	PD	GMR	PR	PD
Higher (vs. lower) maternal BMI										С						
Older (vs. younger) mother																
Higher (vs. lower) maternal education																С
Female (vs. male) child		С														
Later-born (vs. first- born) child					(C)											
Acutely (vs. non- acutely) malnourished																
Anemic (vs. non- anemic)																
Received (vs. did not receive) Vitamin A																
No high (vs. high) AGP or CRP																
Higher (vs. lower) SES												С	С			
Food secure (vs. insecure)																
Improved (vs. unimproved) water quality																
Improved (vs. unimproved) sanitation		(C)														
Rainy (vs. dry) season							С									

medRxiv preprint doi: https://doi.org/10.1101/2021.02.08.21251234; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

AGP = α -1-acid glycoprotein; BMI = body mass index; CRP = C-reactive protein; MD=mean difference; GMR=geometric mean ratio; PR=prevalence ratio; PD=prevalence difference; sTfR = soluble transferrin receptor; ZPP = zinc protoporphyrin. Green indicates stronger effect in the indicated subgroup while blue indicates a stronger effect in the other subgroup. Dark color indicates p-for-interaction < 0.05; light color indicates 0.05 < p < 0.1. The letter "C" indicates that the apparent effect modification is due to the cutoff effect; when "C" is in parentheses, it is partially explained by the cutoff effect.

Figure Legends

- Figure 1: Study flow diagram
- Figure 2: Forest plot of the effect of SQ-LNS on anemia prevalence
- Figure 3: Forest plot of the effect of SQ-LNS on prevalence of iron deficiency (ferritin < 12 $\mu g/L$)

Figure 4: The effect of SQ-LNS provided to children 6-24 months of age compared with a control on (A) hemoglobin concentration, (B) anemia prevalence, (C) moderate-to-severe anemia prevalence, (D) ferritin concentration, (E) iron deficiency, (F) iron deficiency anemia, (G) soluble transferrin receptor concentration, and (H) elevated soluble transferrin receptor, stratified by study-level characteristics. Due to the limited number of studies, we were unable to examine study-level effect modification on all outcomes for all potential modifiers of interest. GMR, ratio of geometric means, MD, mean difference, PR, prevalence ratio, p-diff, p value for the difference in the effect of SQ-LNS between the two levels of the effect modifier.

Figure 5: The effect of SQ-LNS provided to children 6-24 months of age compared with a control on (A) hemoglobin concentration, (B) anemia prevalence, (C) moderate-to-severe anemia prevalence, (D) ferritin concentration, (E) iron deficiency, (F) iron deficiency anemia, (G) soluble transferrin receptor concentration, and (H) elevated soluble transferrin receptor, stratified by individual-level maternal, child and household characteristics. For some biomarkers of micronutrient status, we were unable to generate pooled estimates for effect modification by certain potential individual-level effect modifiers due to an insufficient number of comparisons. GMR, ratio of geometric means, MD, mean difference, PR, prevalence ratio, p-for-interaction, p value for the interaction indicating the difference in effects of SQ-LNS between the two levels of the effect modifier.

Supplemental Tables

Supplemental Table 1: Characteristics of trials included in the individual participant data analysis, outcomes assessed and the analytic contrasts in which they were included

Supplemental Table 2: Amount of SQ-LNS provided (g/day) and nutrient value (per daily ration)

Supplemental Table 3: Descriptive information on potential study-level effect modifiers, by trial

Supplemental Table 4: Descriptive information on potential individual-level effect modifiers, by trial

Supplemental Table 5: Description of biochemical assessments

Supplemental Table 6: Biomarker outcomes at endline among control groups, by trial

Supplemental Table 7: Risk of bias assessment in each trial

Supplemental Table 8: Overview of individual-level effect modification for zinc and vitamin A

Supplemental Figures

Supplemental Figure 1: Summary risk of bias as a percentage of all included studies

Supplemental Figure 2: Sensitivity analyses of main effects of SQ-LNS on biochemical outcomes

Supplemental Figure 3: Forest plots for all main effects of SQ-LNS on biochemical outcomes

Supplemental Figure 4: Forest plots for effects of SQ-LNS on biochemical outcomes stratified by study-level effect modifiers

Supplemental Figure 5: Sensitivity analyses of effect modification of SQ-LNS on biochemical outcomes by study-level effect modifiers

Supplemental Figure 6: Forest plots for effects of SQ-LNS on biochemical outcomes stratified by individual-level maternal and child effect modifiers

Supplemental Figure 7: Forest plots effects of SQ-LNS on biochemical outcomes stratified by individual-level household effect modifiers

Supplemental Figure 8: Sensitivity analyses of effect modification of SQ-LNS on biochemical outcomes by individual-level effect modifiers




Figure 2: Main effect on anemia

Country	Trial	LNS N	Contro N	l					PR (95%	CI/	Fixed W	Random W
Country Bangladesh	JiVitA-4 (35)	457	146					1	•	0.54, 1.28)	0.01	0.03
Bangladesh	RDNS (36)	549	272			· —		'	•	0.54, 1.20) 0.51, 0.84)	0.01	0.06
Bangladesh	WASH-B (37)	234	186			•	⊣ ` │		•	0.24, 0.74)	0.00	0.02
_	iLiNS-Zinc (38)	1957	664	•					•	0.83, 0.91)	0.39	0.10
	PROMIS CS (39)	574	581				■■■		•	0.85, 1.03)	0.10	0.09
Ghana	GHANA (40)	98	96		—		4		•	0.36, 0.72)	0.01	0.04
Ghana	iLiNS-DYAD-G (41)	328	661				—		•	0.73, 1.01)	0.04	0.08
Kenya	WASH-B (42)	350	300			—			•	0.57, 0.81)	0.03	0.08
Madagascar	MAHAY (43)	600	588				├-		0.88 (0	0.78, 1.01)	0.06	0.09
Malawi	iLiNS-DYAD-M (44)	210	432				 1		0.90 (0	0.76, 1.07)	0.03	0.08
Malawi	iLiNS-DOSE (45)	243	82				 1		0.87 (0	0.74, 1.02)	0.04	0.08
Mali	PROMIS CS (46)	953	970						0.82 (0	0.76, 0.88)	0.18	0.10
Zimbabwe	SHINE (HIV-) (47)	1682	1594				 -		0.78 (0	0.70, 0.86)	0.10	0.09
Zimbabwe	SHINE (HIV+) (48)	306	285				—		0.65 (0	0.50, 0.85)	0.01	0.06
	$I^2 = 0.65$, $Tau^2 = 0.02$	8541	6857									
	Fixed						•		0.84 (0.81, 0.87)		
	Random								•	0.72, 0.87)		
						1			<u> </u>	,		
				0.25		0.50	1.0 Ratio	2.0	4.0			
					Favor	s LNS		Favors Contro	I			


Country Trial N N Bangladesh JiVitA-4 (35) 455 144 Bangladesh RDNS (36) 550 272 Bangladesh WASH-B (37) 212 178 Burkina Faso iLiNS-Zinc (38) 315 96 H∎H Burkina Faso PROMIS CS (39) 0.31 0.20 Ghana GHANA (40) 83 82 □ Ghana iLiNS-DYAD-G (41) 0.49 (0.33, 0.73) 0.11 0.14 Kenya WASH-B (42) 298 259 □ □ 0.41 (0.32, 0.53) 0.27 0.19 Malawi iLiNS-DYAD-M (44) □ 0.38 (0.21, 0.67) 0.05 0.09 Mali PROMIS CS (46) □ <t< th=""></t<>
Bangladesh RDNS (36) 550 272
Bangladesh WASH-B (37) 212 178
Burkina Faso iLiNS-Zinc (38) 315 96 H
Burkina Faso PROMIS CS (39) Ghana GHANA (40) 83 82 0.49 (0.33, 0.73) 0.11 0.14 Ghana iLiNS-DYAD-G (41) Kenya WASH-B (42) 298 259 HHHH 0.38 (0.21, 0.67) 0.05 0.09 Malawi iLiNS-DYAD-M (44) Malawi iLiNS-DOSE (45) Mali PROMIS CS (46) Zimbabwe SHINE (HIV-) (47)
Ghana GHANA (40) 83 82 Image: Register of the content of the con
Ghana iLiNS-DYAD-G (41) Kenya WASH-B (42) 298 259 Madagascar MAHAY (43) 83 51 Malawi iLiNS-DYAD-M (44) Malawi iLiNS-DOSE (45) Mali PROMIS CS (46) Zimbabwe SHINE (HIV-) (47)
Kenya WASH-B (42) 298 259 1 0.41 (0.32, 0.53) 0.27 0.19 Madagascar MAHAY (43) 83 51 0.38 (0.21, 0.67) 0.05 0.09 Malawi iLiNS-DOSE (45) ILiNS-DOSE (45) ILINS-DOSE (45) ILINS-DOSE (46) ILINS-DOSE (47) ILINS-
Madagascar MAHAY (43) 83 51
Malawi iLiNS-DYAD-M (44) Malawi iLiNS-DOSE (45) Mali PROMIS CS (46) Zimbabwe SHINE (HIV-) (47)
Malawi iLiNS-DOSE (45) Mali PROMIS CS (46) Zimbabwe SHINE (HIV-) (47)
Mali PROMIS CS (46) Zimbabwe SHINE (HIV-) (47)
Zimbabwe SHINE (HIV-) (47)
Zimbabwe SHINE (HIV+) (48)
I ² = 0.66, Tau ² = 0.05 1996 1082
Fixed 0.44 (0.39, 0.50)
Random 0.41 (0.33, 0.51)
0.15 0.25 0.50 1.0 2.0 4.0 6.67
0.15 0.25 0.50 1.0 2.0 4.0 6.67 Ratio

Favors LNS

Favors Control

Anemia prevalence ratio

B)



medRxiv preprint doi: https://doi.org/10.1101/2021.02.08.21251234; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.


It is made available under a CC-BY 4.0 International license.

C) Moderate-to-severe anemia prevalence ratio


Effect modifier (p-diff)	LNS N	Contro N	I	PR (95% CI)
Anemia burden (p=0.388)				,
High	4035	2825	├──	0.73 (0.54, 0.98)
Moderate	3815	3700	 -	0.68 (0.59, 0.77)
Malaria burden (p=0.282)				· · ·
At least 10%	4363	3486	 1	0.74 (0.57, 0.95)
Less than 10%	3487	3039	 ■ 	0.66 (0.57, 0.77)
Inflammation burden (p=0.100)				,
Low	3913	3796	⊢=	0.63 (0.51, 0.77)
High	3937	2729	⊢= I	0.79 (0.65, 0.96)
Iron dose (p=0.025)				, ,
9 mg ["]	997	668		0.52 (0.36, 0.73)
Less than 9 mg	6853	5857	 ■ 	0.76 (0.66, 0.87)
Supplement duration (p=0.088)				,
12 mo or less		4983		0.74 (0.61, 0.91)
> 12 mo	1852	1542	 ■ 	0.62 (0.54, 0.71)
Frequency of contact (p=0.459)				,
Weekly		1935	- 	0.73 (0.50, 1.06)
Monthly	5014	4590	⊢= -I	0.69 (0.60, 0.79)
Average compliance (p=0.115)				, ,
High	2954	1332	 - I	0.58 (0.43, 0.78)
Low	4296	4605		0.76 (0.63, 0.91)
Sanitation (p=0.290)				,
Improved	2502	2580		0.63 (0.46, 0.88)
Unimproved		2849	⊢= -	0.77 (0.65, 0.91)
Water quality (p=0.934)				, ,
Improved "	1428	1543		0.68 (0.45, 1.02)
Unimproved		3886	⊢= -I	0.72 (0.65, 0.81)
•				
			0.25 0.50 1.0 Ratio	2.0 4.0

Favors LNS

Favors Control



D) Ratio of geometric mean ferritin concentrations




Iron deficiency (ferritin < 12 μg/L) prevalence ratio

Iron deficiency anemia prevalence ratio


F)


Effect modifier (p-diff)	LNS N	Control N					PR (95%	% CI)	
Region (p=0.016)							•	,	
AFR	779	488					0.49	(0.40, 0.60))
SEAR	1217	594					0.31	(0.24, 0.40))
Iron dose (p=0.278)									
9 mg	1143		—					(0.28, 0.49)	,
Less than 9 mg	853		ł				0.47	(0.33, 0.68))
Supplement duration (p=0.081) medRkiv preprint doi: https://doi.org/10.110/M2021.02.08.21291 (whiti 2 wasner certified by geer review) is the author/fur It is made available up	234; this ver	sion posted Februa	nry 10, 202	1. The copyright hold	er for this pre	eprint			
(whit ြည်အနာကျာ oer iffiြေရ by geer review) is the author/fur It is made available u	nd er a CC-B	s 9antel medRxiv 7 4.0 International I	a license t icense .	o di <mark>lsplay the prel</mark> print	in perpetuity.	:		(0.38, 0.63)	,
> 12 mo	1060	709	—				0.34	(0.25, 0.46))
Frequency of contact (p=0.624)									
Weekly	1065		—	-				(0.28, 0.63)	,
Monthly	931	582	H				0.39	(0.32, 0.47))
Sanitation (p=0.105)									
Improved	1182		-					(0.31, 0.48)	,
Unimproved	564	291		 1			0.51	(0.39, 0.66))
Water quality (p=0.105)									
Improved	1182		-					(0.31, 0.48)	,
Unimproved	564	291					0.51	(0.39, 0.66))
			0.25	0.50	1.0	2.0	4.0		
		,	0.20	0.50	Ratio	۷.0	4.0		
			Fa	vors LNS		Favors Contro	ol		



G) Ratio of geometric mean soluble transferrin receptor concentrations

H) Elevated soluble transferrin receptor prevalence ratio





Effect modifier (p-for-interaction)	LNS Control N N		MD (95% CI)	Effect modifier (p-for-interaction)	LNS Control		PR (95% CI)
Maternal BMI (p=0.320)	IN IN		(93 % CI)	Maternal BMI (p=0.637)	IN IN		(9376 CI)
At least 20 kg/m²	4883 4084	⊢= -1	2.97 (2.39, 3.55)	At least 20 kg/m²	4883 4084	l = l	0.84 (0.81, 0.87)
Less than 20 kg/m ²	2179 1658	⊢=	3.13 (2.18, 4.07)	Less than 20 kg/m ²	2179 1658	 = 	0.86 (0.82, 0.90)
Maternal age (p=0.015)				Maternal age (p=0.041)			
At least 25 y	4401 3563	⊢= -1	3.33 (2.71, 3.94)	At least 25 y	4401 3563	H ≡ H	0.83 (0.80, 0.86)
Less than 25 y	3919 3082	⊢= -1	2.61 (1.92, 3.29)	Less than 25 y	3919 3082	I ≡ I	0.87 (0.83, 0.90)
Maternal education (p=0.21	2)			Maternal education (p=0.62	1)		
Primary or greater	3635 3269	 ■ 	2.73 (2.15, 3.32)	Primary or greater	3139 2909	 ■ 	0.80 (0.75, 0.86)
Incomplete or no formal	4781 3472	 ■ 	3.08 (2.26, 3.91)	Incomplete or no formal	2704 2737	 ■ 	0.87 (0.82, 0.91)
Child sex (p=0.449)				Child sex (p=0.039)			
Male	4277 3438	 ■ 	3.07 (2.42, 3.71)	Male	4277 3438	l = l	0.87 (0.84, 0.90)
Female	4261 3416	 ■ 	2.79 (2.18, 3.39)	Female	4261 3416	I≡I	0.82 (0.78, 0.85)
Child birth order (p=0.003)				Child birth order (p=0.156)			
Later born	6174 5062	 ■ 	3.25 (2.71, 3.79)	Later born	6026 5001	I ≡ I	0.83 (0.80, 0.86)
Firstborn medRxiv preprint doi: https://doi.org/10.1101/2021.02.08. (which was not certified by peer review) is the auth	2226 1676 21251234; this version posted February 10, 2021. The c	copyright holder for this preprint	2.28 (1.47, 3.10)	Firstborn	2170 1666	 = 	0.87 (0.83, 0.91)
(which was not certified by peer review) is the auth Acute mainutrition (piero: 659)	nor/funder, who has granted medRxiv a license to displate under a CC-BY 4.0 International license.	y the preprint in perpetuity.		Acute malnutrition (p=0.393)		
No	4424 3125	 ■ 	2.34 (1.73, 2.96)	No	4194 3050	I≡I	0.85 (0.82, 0.89)
Yes	765 399		⊣ 3.50 (1.64, 5.35)	Yes	752 392	 ■ 	0.85 (0.80, 0.91)
Inflammation (p=0.712)				Inflammation (p=0.006)			
Not inflamed	1845 1378		3.17 (2.34, 3.99)	Not inflamed	1459 1137		0.66 (0.58, 0.75)
High AGP or CRP	1266 976		3.00 (1.99, 4.00)	High AGP or CRP	959 825		0.85 (0.77, 0.95)
Anemia (p=0.063)				Anemia (p=0.683)			
Normal	746 699	├──	1.63 (0.32, 2.95)	Normal	746 699		0.85 (0.76, 0.96)
Anemic	2460 1276	├──	H 3.91 (2.54, 5.28)	Anemic	2460 1276	 ■ 	0.87 (0.83, 0.91)
Vitamin A dose (p=0.808)				Vitamin A dose (p=0.760)			
Received VitA	2013 1882	 ■ 	2.19 (1.42, 2.96)	Received VitA	1993 1864		0.78 (0.71, 0.85)
Not treated	1588 1634	 ■ 	2.39 (1.56, 3.21)	Not treated	1572 1625	- ■ -	0.75 (0.68, 0.82)
SES (p=0.528)				SES (p=0.762)			
At least median	4509 3354	 ■ 	3.41 (2.78, 4.03)	At least median	4395 3261	l≡l	0.83 (0.80, 0.87)
Less than median	3837 3348	 ■ 	2.75 (2.09, 3.42)	Less than median	3717 3255	H ≡ H	0.85 (0.82, 0.89)
Food security (p=0.470)				Food security (p=0.949)			
Mild to secure	4366 3314	 ■ 	2.53 (1.94, 3.12)	Mild to secure	3837 3056	I≡I	0.84 (0.80, 0.87)
Moderate to severe	2207 1610	 ■ 	3.18 (2.23, 4.13)	Moderate to severe	2046 1536	ŀ ≡ I	0.86 (0.81, 0.90)
Water quality (p=0.746)				Water quality (p=0.009)			
Improved	2562 2312		2.91 (2.00, 3.82)	Improved	2478 2266	I ≡ I	0.82 (0.79, 0.86)
Unimproved	2808 1947	 ■ 	3.49 (2.46, 4.51)	Unimproved	2787 1933	 =	0.88 (0.84, 0.92)
Sanitation (p=0.607)				Sanitation (p=0.092)			
Improved	2398 2202	 ■ 	2.60 (1.84, 3.37)	Improved	1655 1391	 ■ 	0.85 (0.80, 0.91)
Unimproved	3637 2489	 ■ 	3.19 (2.33, 4.05)	Unimproved	1438 1405	 ■ 	0.79 (0.73, 0.85)
Season (p=0.190)				Season (p=0.434)			
Dry	5383 4199	 ■ 	2.75 (2.17, 3.32)	Dry	5094 3934	I ≡ I	0.85 (0.82, 0.88)
Rainy	2205 1685	 ■ 	2.41 (1.58, 3.24)	Rainy	2188 1665	 ■ 	0.87 (0.82, 0.92)
	_5	0 4			0	.50 1.0	2.0
	– 5	Difference	,		U	Ratio	۷.0
	Favors 0	Control Favors LNS				Favors LNS Favor	rs Control

B)

Effect modifier (p-for-interaction) Maternal BMI (p=0.459)	LNS Control N N		PR (95% CI)	Effect modifier (p-for-interaction) Maternal BMI (p=0.221)	LNS Control N N		GMR (95% CI)
At least 20 kg/m ²	4272 3224	 ■ 	0.71 (0.66, 0.76)	At least 20 kg/m²	753 454	 ■ 	1.67 (1.53, 1.83)
Less than 20 kg/m ²	1954 1420	├■ - 	0.72 (0.67, 0.78)	Less than 20 kg/m ²	589 333	 ■ 	1.52 (1.39, 1.67)
Maternal age (p=0.260)				Maternal age (p=0.112)			,
At least 25 y	4040 3345		0.71 (0.65, 0.77)	At least 25 y	897 510	 ■ 	1.65 (1.53, 1.78)
Less than 25 y	3495 2881	 -■- 	0.74 (0.69, 0.80)	Less than 25 y	1091 564	 ■ 	1.49 (1.39, 1.59)
Maternal education (p=0.43	7)			Maternal education (p=0.928	3)		,
Primary or greater	1019 716		0.66 (0.56, 0.77)	Primary or greater	1088 625	 ■ 	1.52 (1.42, 1.62)
Incomplete or no formal	4395 3161	 ■ 	0.74 (0.70, 0.79)	Incomplete or no formal	591 357	 ■ 	1.51 (1.38, 1.65)
Child sex (p=0.692)				Child sex (p=0.649)			,
Male	3866 3237	 ■ 	0.71 (0.67, 0.76)	Male	987 519	 ■ 	1.57 (1.46, 1.69)
Female	3883 3189	 -	0.73 (0.66, 0.79)	Female	1006 563	 ■ 	1.56 (1.45, 1.67)
Child birth order (p=0.416)				Child birth order (p=0.040)			
medRxiv preprint doi: https://doi.org/10.1101/2021.02.08. (which was dot (defined by peer review) is the autil It is made availe	212512347this version posted February 10, hor/funder, who has gamed medRxiv a licen	2021. The copyright holder for this preprint use to display the preprint in perpetuity.	0.71 (0.66, 0.76)	Later born	1179 693	 = 	1.64 (1.54, 1.75)
Firstborn	1734 1493). ├── ┤	0.73 (0.67, 0.79)	Firstborn	812 380	 ■ 	1.40 (1.29, 1.53)
Inflammation (p=0.197)				Acute malnutrition (p=0.023)			
Not inflamed	1130 813	 -	0.63 (0.51, 0.77)	No	1085 427	 ■ 	1.47 (1.38, 1.57)
High AGP or CRP	761 664		0.76 (0.66, 0.87)	Yes	211 68	├─	→ 1.85 (1.53, 2.24)
Anemia (p=0.686)				Inflammation (p=0.089)			
Normal	557 344	├──	0.73 (0.58, 0.92)	Not inflamed	1114 614	 ■ 	1.65 (1.53, 1.76)
Anemic	2370 1069	 ■ 	0.73 (0.67, 0.80)	High AGP or CRP	882 468	⊢= -∣	1.48 (1.37, 1.60)
Vitamin A dose (p=0.874)				Vitamin A dose (p=0.348)			
Received VitA	1587 1353 -		0.66 (0.54, 0.82)	Received VitA	665 360	⊢= -I	1.48 (1.38, 1.59)
Not treated	1278 1306		0.77 (0.63, 0.94)	Not treated	520 305	⊢=	1.62 (1.45, 1.81)
SES (p=0.244)				SES (p=0.204)			
At least median	4094 3138	├■	0.72 (0.67, 0.78)	At least median	1048 563	 ■ 	1.63 (1.52, 1.74)
Less than median	3464 3142	 ■ 	0.70 (0.65, 0.76)	Less than median	944 514	 ■ 	1.53 (1.42, 1.64)
Food security (p=0.938)				Food security (p=0.245)			
Mild to secure	3390 2395	 ■ 	0.72 (0.67, 0.78)	Mild to secure	1314 726	 ■ 	1.60 (1.49, 1.71)
Moderate to severe	1874 1269		0.75 (0.68, 0.83)	Moderate to severe	578 260	 ■ 	1.47 (1.35, 1.61)
Water quality (p=0.952)				Water quality (p=0.408)			
Improved	2273 2068		0.79 (0.71, 0.87)	Improved	306 187	 ■ 	1.69 (1.50, 1.91)
Unimproved	2670 1846	├■	0.73 (0.68, 0.78)	Unimproved	347 161	├-= -	1.53 (1.34, 1.74)
Sanitation (p=0.004)				Sanitation (p=0.512)			
Improved	1585 1336		0.74 (0.65, 0.84)	Improved	760 328	 ■ 	1.45 (1.34, 1.57)
Unimproved	1186 1176		0.60 (0.51, 0.71)	Unimproved	410 232	 ■ 	1.61 (1.43, 1.80)
Season (p=0.189)				Season (p=0.012)			
Dry	3164 2289	- ■ -	0.73 (0.67, 0.79)	Dry	1010 513	 ■ 	1.44 (1.34, 1.55)
Rainy	1745 1384	 ■ 	0.78 (0.71, 0.86)	Rainy	887 513	 -= 	1.74 (1.62, 1.87)
	0.50	1.0 Ratio	2.0		0.50	1.0 2.0 Ratio)
	F	Favors LNS Favors (Control		Favo	ors Control Favors LNS	

D)

F)

Effect modifier	LNS	Control			PR
(p-for-interaction)	N	N			(95% CI)
Maternal BMI (p=0.786)					
At least 20 kg/m ²	753	454			0.47 (0.38, 0.57)
Less than 20 kg/m ²	589	333			0.45 (0.36, 0.55)
Maternal age (p=0.131)					
At least 25 y	897	510	 ■ 		0.44 (0.37, 0.52)
Less than 25 y	1091	564			0.48 (0.40, 0.57)
Maternal education (p=0.783)					
Primary or greater	996	544			0.36 (0.29, 0.46)
Incomplete or no formal	517	309			0.36 (0.27, 0.47)
Child sex (p=0.771)					
medRxiv preprint doi: https://doi.org/10.1101/2021.02.08.212 (which certified by peer review) is the author/ It is made available	51234; this vertically the funder a CC-	ersion posted Februa a granted medRxiv BY 4.0 International	ary 10, 2021. The copyright holder for a license to deptay the preprint in pe license.	this preprint rpetuity.	0.41 (0.35, 0.50)
Female	1006		 ■ 		0.45 (0.38, 0.55)
Child birth order (p=0.101)					
Later born	1118	656	 ■ 		0.43 (0.37, 0.51)
Firstborn	791	369			0.56 (0.46, 0.68)
Inflammation (p=0.951)					
Not inflamed	880	412	⊢=		0.43 (0.35, 0.53)
High AGP or CRP	821	410	├─		0.49 (0.40, 0.60)
Vitamin A dose (p=0.528)					
Received VitA	649	344			0.37 (0.28, 0.49)
Not treated	505	296	 ■ 		0.42 (0.33, 0.53)
SES (p=0.847)					
At least median	1048	563	 ■ 		0.47 (0.40, 0.54)
Less than median	944	514	⊢= ⊢		0.43 (0.36, 0.52)
Food security (p=0.859)					
Mild to secure	1269	696	- ■ - 		0.42 (0.36, 0.50)
Moderate to severe	559	253	├─		0.45 (0.36, 0.58)
Water quality (p=0.976)					
Improved	231	143	 ■ 		0.54 (0.44, 0.66)
Unimproved	328	147			0.52 (0.41, 0.66)
Season (p=0.002)					
Dry	1010	513			0.53 (0.45, 0.64)
Rainy	887	513	<u></u>		0.37 (0.31, 0.45)
		^	25 0.50 4	0 20 4	
		U		.0 2.0 4 ntio	1.0
			Favors LNS	Favors Control	

Effect modifier (p-for-interaction)	LNS N	Contro N	I			PR (95% CI)
Maternal BMI (p=0.521)						
At least 20 kg/m ²	665	360				0.38 (0.28, 0.52)
Less than 20 kg/m ²	476	253				0.46 (0.35, 0.60)
Child sex (p=0.208)						
Male	569	309	- ■ 			0.46 (0.34, 0.62)
Female	603	322				0.35 (0.27, 0.46)
Child birth order (p=0.904)						
Later born	833	455	├ ■			0.42 (0.33, 0.53)
Firstborn	340	176				0.37 (0.25, 0.55)
Inflammation (p=0.388)						
Not inflamed	656	335				0.32 (0.23, 0.44)
High AGP or CRP	518	296	├─			0.47 (0.37, 0.61)
SES (p=0.751)						
At least median	623	332	 ■ 			0.38 (0.30, 0.49)
Less than median	550	299	 ■ 			0.39 (0.29, 0.52)
						7
			0.25 0.50	1.0 Ratio	2.0	4.0
			Favors LNS		Favors Control	

Effect modifier		Control		GMR
(p-for-interaction)	N	N		(95% CI)
Maternal BMI (p=0.955)			1	
At least 20 kg/m ²	753	454	I≡I	0.82 (0.79, 0.86)
Less than 20 kg/m ²	589	333	H ≡ H	0.83 (0.79, 0.87)
Maternal age (p=0.213)				
At least 25 y	696	440	H ≡ H	0.84 (0.80, 0.88)
Less than 25 y	841	491	 = 	0.83 (0.80, 0.86)
Maternal education (p=0.576)			
Primary or greater	791	532	H	0.84 (0.81, 0.88)
Incomplete or no formal	435	306	 ■ 	0.82 (0.78, 0.87)
Child sex (p=0.268)				
nedRxiv preprint doi: https://doi.org/10.1101/2021.02.08.21: (which was lost certified by peer review) is the author	251234; this v /funde Owno h	ersion posted February as granted medRxiv a BY 4.0 International lice	10, 2021. The copyright holder for this preprint license to display the preprint in perpetuity.	0.81 (0.77, 0.85)
Female		489	 ■ 	0.85 (0.82, 0.88)
Child birth order (p=0.731)				
Later born	1065	661	I ≡ I	0.83 (0.80, 0.86)
Firstborn	473	269	ŀ ≡ ŀ	0.82 (0.78, 0.86)
Inflammation (p=0.478)				
Not inflamed	930	568	H = H	0.84 (0.81, 0.87)
High AGP or CRP	612	370	H ≡ H	0.82 (0.78, 0.86)
Vitamin A dose (p=0.373)				
Received VitA	526	323	 ■ 	0.85 (0.81, 0.89)
Not treated	387	264	 ■ 	0.85 (0.81, 0.90)
SES (p=0.373)				
At least median	806	485	H ≡ H	0.82 (0.78, 0.85)
Less than median	733	448	H ≡l	0.84 (0.80, 0.87)
Food security (p=0.189)				
Mild to secure	977	615	I ≡ I	0.81 (0.78, 0.84)
Moderate to severe	461	227	H ≡ H	0.86 (0.82, 0.91)
Water quality (p=0.039)				
Improved	306	187	 = 	0.75 (0.70, 0.81)
Unimproved	347	161	 ■ 	0.82 (0.77, 0.87)
Season (p=0.865)				
Dry	747	442	I ≡ I	0.84 (0.80, 0.87)
Rainy	696	440	 = 	0.82 (0.78, 0.86)
		0.5		2.0
			Ratio Favors LNS Favors	s Control

Effect modifier (p-for-interaction)	LNS N	Control N			PR (95% CI)
Maternal BMI (p=0.126)	660	357			0.70 (0.61, 0.90)
At least 20 kg/m²	660 4 7 0				0.70 (0.61, 0.80)
Less than 20 kg/m ²	470	252			0.62 (0.53, 0.72)
Maternal age (p=0.585)	606	440			0.05 (0.50, 0.74)
At least 25 y	696	440			0.65 (0.58, 0.74)
Less than 25 y	841	491	├─■ ─1		0.64 (0.57, 0.72)
Maternal education (p=0.227)		407			0.00 (0.54, 0.70)
Primary or greater	714	467	, <u> </u>		0.62 (0.54, 0.70)
Incomplete or no formal	428	293	-		0.73 (0.64, 0.84)
Child sex (p=0.787)	750	4.40			0.05 (0.50, 0.70)
Male -	753	449			0.65 (0.58, 0.73)
Female	786	489	├ ■		0.62 (0.55, 0.71)
Child birth order (p=0.638)					
Later born	1004		├-		0.65 (0.58, 0.72)
Firstborn	452	258	├ = 		0.58 (0.50, 0.67)
Inflammation (p=0.761)					
Not inflamed	930	568	 		0.66 (0.59, 0.75)
High AGP or CRP	612	370	 ■ 		0.63 (0.55, 0.72)
Vitamin A dose (p=0.344)					
Received VitA	510	307			0.65 (0.55, 0.77)
Not treated	372	255	├ ■		0.71 (0.63, 0.81)
SES (p=0.066)					
At least median	806	485			0.60 (0.53, 0.68)
Less than median	733	448	 ■ 		0.71 (0.62, 0.80)
Food security (p=0.366)					
Mild to secure	761	446			0.63 (0.56, 0.71)
Moderate to severe	401	181			0.69 (0.57, 0.84)
Water quality (p=0.114)					
Improved	231	143	⊢ ■		0.59 (0.49, 0.69)
Unimproved	328	147			0.65 (0.55, 0.78)
Season (p=0.154)					
Dry	747	442	⊢=		0.58 (0.51, 0.66)
Rainy	696	440	 -		0.68 (0.60, 0.76)
		0	.50 1.	0 2.	0
			Ra ⁻ Favors LNS	tio Favors Control	